

EXHIBIT D



US008859562B2

(12) **United States Patent**
Helleday

(10) **Patent No.:** **US 8,859,562 B2**
(45) **Date of Patent:** **Oct. 14, 2014**

(54) **USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER**

(75) Inventor: **Thomas Helleday**, Stockholm (SE)

(73) Assignee: **The University of Sheffield**, Sheffield (GB)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 2568 days.

(21) Appl. No.: **10/555,507**

(22) PCT Filed: **Jul. 23, 2004**

(86) PCT No.: **PCT/GB2004/003235**

§ 371 (c)(1),

(2), (4) Date: **Sep. 15, 2006**

(87) PCT Pub. No.: **WO2005/012524**

PCT Pub. Date: **Feb. 10, 2005**

(65) **Prior Publication Data**

US 2007/0179160 A1 Aug. 2, 2007

(30) **Foreign Application Priority Data**

Jul. 25, 2003 (GB) 0317466.1

(51) **Int. Cl.**

A61K 31/495 (2006.01)

A61K 31/33 (2006.01)

A61K 31/435 (2006.01)

A61K 38/00 (2006.01)

C07D 487/06 (2006.01)

C12N 15/113 (2010.01)

A61K 31/5517 (2006.01)

(52) **U.S. Cl.**

CPC **C07D 487/06** (2013.01); **A61K 38/005** (2013.01); **C12N 15/1137** (2013.01); **A61K 31/5517** (2013.01); **C12Y 204/0203** (2013.01); **C12N 2310/14** (2013.01)

USPC **514/258.1**; 514/299; 514/388

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,098,861 A 3/1992 Blackstone
5,484,951 A 1/1996 Kun et al.
5,519,053 A 5/1996 Kun et al.
5,652,367 A 7/1997 Kun et al.
6,548,494 B1 * 4/2003 Webber et al. 514/220
7,072,771 B2 * 7/2006 Oliveira 702/27
7,087,637 B2 8/2006 Grandel et al.
7,176,188 B2 2/2007 Desnoyers
2003/0229004 A1 12/2003 Zarling et al.
2005/0227919 A1 10/2005 Ashworth et al.
2006/0142231 A1 6/2006 Ashworth et al.

FOREIGN PATENT DOCUMENTS

EP 0600831 A1 11/1993
WO 95/24379 9/1995
WO 9908680 A1 * 2/1999
WO 00/42040 7/2000
WO 01/16136 3/2001
WO 02/12239 2/2002
WO 02/36576 A1 5/2002
WO 02/090334 A1 11/2002
WO 03/014090 A1 2/2003
WO 03/063874 A1 8/2003
WO 03/070234 A1 8/2003
WO 03/093261 A1 11/2003
WO 2004/008976 A1 1/2004

OTHER PUBLICATIONS

Gan et al., Specific interference with gene expression and gene function mediated by long dsRNA in neural cells, *Journal of Neuroscience Methods*, 121, 2002, pp. 151-157.*

Cecil Textbook of Medicine, 1997, 20th Edition, vol. 1, pp. 1007-1010.*

Sausville et al. (*Cancer Research*, 2006, vol. 66, pp. 3351-3354).*

Johnson et al. (*British J. of Cancer*, 2001, 84(10):1424-1431).*

Thacker, J., *Cancer Letters*, 2005, vol. 219, pp. 125-135.*

BG483078, <http://mgc.nci.nih.gov/>, National Institutes of Health, Mammalian Gene Collection (MGC, Unpublished, 1999, Contact: Robert Strausberg, Ph.D, Tissue Procurement: CLONTECH Laboratories, Inc.

Elbashir et al., Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells, *Nature*, 2001, 411: 494-498.

Larminat et al., Deficiency in BRCA2 Leads to Increase in Nonconservative Homologous Recombination, *Oncogene*, 2002, 21: 5188-5192.

Massuda et al., PARP Inhibitor, Down-Regulates Metastasis Associated S100A4 (MTS1) and Suppresses Invasion of Breast Cancer Cells In Vitro, *Proceedings of the American Association for Cancer Research*, 2003, 44(2nd ed), 867-868.

Schultz et al., Poly (ADP-Ribose) Polymerase (PARP-1) Has a Controlling Role in Homologous Recombination, *Nucleic Acids Research*, 2003, 31(17): 4959-4964.

Shall et al., Poly(DP-Ribose) Polymerase-1: What Have We Learned From the Deficient Mouse Model?, *Mutation Research*, 2000, 460: 1-15.

Weltin et al., Effect of 6(5H)-Phenanthridinone, An Inhibitor of Poly(ADP-Ribose) Polymerase, on Cultured Tumor Cells, *Oncology Research*, 6(9): 399-403.

(Continued)

Primary Examiner — James D Anderson

(74) *Attorney, Agent, or Firm* — Bozicevic, Field & Francis LLP; Pamela J. Sherwood

(57) **ABSTRACT**

The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

1 Claim, 20 Drawing Sheets

US 8,859,562 B2

Page 2

(56)

References Cited

OTHER PUBLICATIONS

Gallmeier et al., Absence of Specific Cell Killing of the BRCA2-Deficient Human Cancer Cell Line CAPAN1 by Poly(ADP-Ribose) Polymerase Inhibition, 2005 *Cancer Biol. & Ther.*, 4(7): 703-706.

McCabe et al., BRCA2-Deficient CAPAN-1 Cells Are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase, 2005, *Cancer Biol. & Ther.*, 4(9): 934-936.

Jönsson, Göran; et al., "High-Resolution Genomic Profiles of Breast Cancer Cell Lines Assessed by Tiling BAC Array Comparative Genomic Hybridization", *Genes, Chromosomes and Cancer*, 2007, 46:543-558.

Sanger Institute database entry for MDA_MB-231, Catalogue of Somatic Mutations in Cancer, 2 pgs.

Turner, Nicholas; et al., "Hallmarks of 'BRCAness' in sporadic cancers", *Nature Reviews*, Oct. 2004, 4:1-6.

Wooster, Richard; et al., "Breast and Ovarian Cancer", *The New England Journal of Medicine*, Jun. 5, 2003, 348:2339-47.

Bernstein, C., et al., "DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis," (2002) *Mutation Research*, 511:147-178.

Bryant, H., et al., "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase," (2005) *Nature*, 434:913-917.

Farmer, H., et al., "Targeting the DNA repair defect in *BRCA* mutant cells as a therapeutic strategy," (2005) *Nature*, 434:917-921.

Watchers, F., et al., "Selective targeting of homologous DNA recombination repair by gemcitabine," (2003) *Int. J. Radiation Oncology Biol. Phys.*, 57(2):553-562.

Banasik, Marek; et al., "Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferase", *The Journal of Biological Chemistry*, Jan. 25, 1992, 267(3):1569-1575.

Calabrese, Christopher R; et al., "Identification of Potent Nontoxic Poly (ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies", *Clinical Cancer Research*, Jul. 2003, 9:2711-2718.

Cepeda, Victoria; et al., "Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy", *Recent Patents on Anti-Cancer Drug Discovery*, 2006, 1:39-53.

Dillon, Krystyna J; et al., "A FlashPlate Assay for the Identification of PARP-1 Inhibitors", *J. Biomol Screen*, 2003, 8(3):347-352.

Ferraris, Dana; et al., "Design and Synthesis of Poly ADP-ribose Polymerase-1 Inhibitors. 2. Biological Evaluation of Aza-5[H]-phenanthridin-6-ones as Potent, Aqueous-Soluble Compounds for the Treatment of Ischemic Injuries", *J. Med. Chem.*, 2003, 46:3138-3151.

Griffin, RJ; et al., "The role of inhibitors of poly (ADP-ribose) polymerase as resistance-modifying agents in cancer therapy", *Biochimie*, 1995, 77:408-422.

McCabe, Nuala; et al., "Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly (ADP-Ribose) Polymerase Inhibition", *Cancer Res*, Aug. 15, 2006, 66(16):8109-8115.

Virag, Laszlo; et al., "The Therapeutic Potential of Poly (ADP-Ribose) Polymerase Inhibitors", *Pharmacological Reviews*, 2002: 54(3):375-429.

Dudas, Andrej; et al., "DNA double-strand break repair by homologous recombination", *Mutation Research*, 2004, 566:131-167.

Hoeymakers, Jan H. J.; et al., "Genome maintenance mechanisms for preventing cancer", *Nature*, May 17, 2001, 411:366-374.

Khanna, Kum Kum; et al., "DNA double-strand breaks: signaling, repair and the cancer connection", *Nature Genetics*, Mar. 2001, 27:247-254.

Fong; et al., "AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study", *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 5510).

Hao; et al., "BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR", *Int. J. Cancer* (2007), 121:39-46.

Lau; et al., "Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer", *EORTIC 2008 Geneva*, poster #557.


Calabrese; et al., "Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies", *Clinical Cancer Research* (2003), 9:2711-2718.

Berthet; et al., "DNA repair inhibitors", *Expert Opinion on Therapeutic Patents* (1999), 9(4):401-415.

Perkins, et al., "Novel Inhibitors of Poly(ADP-ribose) Polymerase/ PARP1 and PARP2 Identified Using a Cell-based Screen in Yeast", *Cancer Research* (2001), 61:4175-4183.

* cited by examiner

Figure 1.



U.S. Patent

Oct. 14, 2014

Sheet 2 of 20

US 8,859,562 B2

Figure 2.




Figure 3





Figure 4




U.S. Patent

Oct. 14, 2014

Sheet 5 of 20

US 8,859,562 B2

Figure 5A






U.S. Patent

Oct. 14, 2014

Sheet 6 of 20

US 8,859,562 B2



U.S. Patent

Oct. 14, 2014

Sheet 7 of 20

US 8,859,562 B2






FIG. 6

U.S. Patent

Oct. 14, 2014

Sheet 8 of 20

US 8,859,562 B2




Fig. 7




FIGURE 9

1 cgcccgccca gccccggggg cagggaaagc ctaaattacg gaattaccgc gagcaaggag
 61 cgcggaatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tgatgggaat
 121 ctttgcaaat tgtatcttct gttgaaagt gaagtactta cctcagcagc agaagaaaaa
 181 gctacaaact gacatlaagg aaaatggcgg aaagtttcc tttcgttaa atcctcagtg
 241 cacacatata atcttagata atgctgatgt tctgagtcag faccaactga attctatcca
 301 aaagaaccac gtcatattg caaaccacaga ttttatatgg aaatctatca gagaaaagag
 361 actcttggat gtaaagaatt atgaccta taagccctg gacatcacac cacctctga
 421 tcagaaggcg agcagttctg aagtgaanaa agaaggctta tgcgggaca gtgccacaga
 481 ggaggaagac actgtggaac tcactgagtt tggatgcag aatgttgaaa ttctcatct
 541 tctcaagat ttgaagtig caaaatataa caccttggag aaagtgggaa tggaggagg
 601 ccaggaagct gtgtgtgtgg agcttcagtg ttgcgggac tccagggact gtcttctct
 661 gatactctca cacttctcc tggatgatgg catggagact agaagacagt ttgctataa
 721 gaaaacctct gaagatgcaa gtgaatacti tgaanaattac attgaagaac tgaagaaca
 781 aggtattcta ctaagagaac attcacacc tgaagcaacc caattagcat ctgaacaatt
 841 gcaagcattg cttttggagg aagtcataa ttcaagcact ctgagccaag aggtgagcga
 901 tttagtagag atgatttggg cagaggccct gggccacctg gaacacatgc ttctcaagcc
 961 agtgaacagg attagctca acgatgtgag caaggcagag gggattctcc ttctagtaa
 1021 ggcagcactg aaaaatggag aacacagaga gcaattgcaa aagatgatga cagagtttta
 1081 cagactgata cctcacaag gcacaatgcc caaagaagtg aacctgggac tattggctaa
 1141 gaaagcagac ctctgccagc taataagaga catggttaat gtctgtgaaa ctaattgtc
 1201 caaaccacac ccaccatccc tggccaataa ccgagctttg aggtgcaaaa ttgagcatgt
 1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gttttgcaga atcatcacag
 1321 taagagccca gtggatgtct tgcagatatt tagagttggc agagtgaatg aaaccacaga
 1381 gttttgagc aaacttggta atgtgaggcc ctgttgcat ggttctctg taaaaacat
 1441 cgtgggaatc ttgtgtcgag ggttgccttt acccaaaagta gtggaagatc gtgtgtgca
 1501 aagaacagac gtcggaacac ttggaagtgg gatatttct agtgattcgc tcagtacaag
 1561 tatcaagtac tcacaccgg gagagacaga tggcaccaga ctctgtctca tttgtacgt
 1621 agccctcgga aagtgtatgg acttacatga gaaggacttt tcttaactg aagcaccac
 1681 aggtctagac agtgtgcatg gagtttaca aacagcctct gtcaccacag actttgagga
 1741 tgatgaattt gttgtctata aaaccaatca ggttaaaatg aaatatatta taaatttct
 1801 catgcttga gatcagataa aggaacttca tctagtgtat catactgaat tagaggaata
 1861 cagacctgag ttttcaaat ttcaaaagt tgaagattac cagttaccag atgcaaaaac
 1921 ttcagcagc accaaggcgg gctccagga tgccttggg aacttgggtc ctctggagga
 1981 tgtccacatc aaaggagaga tcatagacac ttagcccgag gtcattgttt ttcagacata
 2041 cacaataaaa agtcacgtgc ccattgagc aaaatatata ttctcttgg atgacaaggc
 2101 cgtgtgtgt ggttcgaag ccttcacaa tgggaagcac atagtggag agattaaaga
 2161 gaaggaagaa gccagcaag agtacctaga agccgtgacc cagggccatg gogcttacct
 2221 gatgagtcag gatgtccgg acgttttct tgaagtgtt ggaaacttac cccctaagc
 2281 taaggttctt ataaaaata cctacatcac agaactcagc atcctgggca ctgttggtgt
 2341 ctttttcatg cccgccaccg tagcaccctg gcaacaggac aaggcttga atgaaaacct
 2401 tcaggataca gttagagaaga ttgtataaa agaaatagga acaagcaaa gcttctctt
 2461 gactatgtct attgagatgc cgtacgtgat tgaattcatt ttcagtata ctcatgaact
 2521 gaaacaaaag cgcacagact gcaaagctgt cattagcacc atggaaggca gctccttaga
 2581 cagcagtgga tttctctcc acatcggttt gtctgtgccc tatctccaa gaatgtgggt
 2641 tgaaaaacat ccagaaaaag aaagcgaggc ttgcatgctt gtcttcaac ccgatctga
 2701 tgtcgacctc cctgacctag ccaatgagag cgaagtgaat atttgtcttg actgtccag
 2761 ttccatggag ggtgtgacat tcttcaagc caaggaaac gccttgcag cgctgtcctt

2821 ggtgggtgag aagcagaaag taaatattat ccagttcggc acaggttaca aggagctatt
 2881 ttctatcct aagcatafca caagcaatc cgccggcagca gagttcatca tgtctgccac
 2941 acctaccatg gggaacacag acttctggaa aacactccga tatcttagct taftgtacc
 3001 tgctcgaggg tcacggaaca tctcctgggt gtctgatggg cacctccagg atgagagcct
 3061 gacattacag ctctgaaga ggagccgccc gcacaccagg ttattcgctt gcggtatcgg
 3121 ttctacagca aatcgtcacg tcttaaggat ttgtccag tctggtgccg gagtattga
 3181 alattttaat gcaaatcca agcatagttg gagaaaacag atagaagacc aaatgaccag
 3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc
 3301 gcccagggcc ctgcaggccc cagcccagggt gccatccttg ttgcgaatg atcactcct
 3361 tgtctatgga ttcattctc actgcacaca ggcaactctg tgtgactaa tcaagagaa
 3421 agaatttgt acaatgggtg cgactactga gcttcagaag acaactggaa ctatgatcca
 3481 caagctggca gcccgagctc taatcagaga ttatgaagat ggcatcttc acgaaaatga
 3541 aaccagtcag gagatgaaaa acaaacctt gaaatctctg attattaaac tcagtaaaga
 3601 aaactctctc ataacacaat ttacaagctt tctggcagtt gagaaaagg atgagaatga
 3661 gtcacctttt cctgatatic caaaagtctc tgaactatt gccaaaag atgtagactt
 3721 cctgcccac atgagctggc agggggaacc ccaagaagcc gtcaggaacc agtctcttt
 3781 agcatcctct gagtggccag aattacgtt atccaaacga aaacatagga aaattccatt
 3841 ttccaaaaga aaaatggaat tatctcagcc agaagtctt gaagatttg aagaggatgc
 3901 cttaggtgta ctaccagctt tcacatcaaa ttggaacgt ggacgtgtgg aaaagctatt
 3961 ggatttaagt tggacagagt catgtaaacc aacagcaact gaaccactat ttaagaaagt
 4021 cagtcacatg gaaacatcta ctctagctt ttctctatt ttggctccgg ccgttggttc
 4081 ctatcttacc ccgactacc gcgctcacag tctgtctcc ttgtctttg cctcatatc
 4141 tcaggtagct agttcgggt cagctgctc tccagacag ttgatgcat ctcaattcag
 4201 ccaaggeect gtgcctggca ctgtgtctga ctgcatcca cagtcggcgt ctgtccac
 4261 aggacctccc cagaaccac ctctgcacc ctattgtggc attgtttt caggagctc
 4321 attagctct gcacagtctg ctccactgca acatctgga ggcttacta ccaggccttc
 4381 tctgtggacc ttccctgagc tggattctc ccagcttcat ttctcttc ctacagacc
 4441 tgatcccatc agaggtttg ggtctatca tccctctgt tactctctt ttatttca
 4501 acctccgca gcctctttga ctgccaacct taggtgcca atggcctctg ctctacctga
 4561 ggctctttgc agtcagtc ccgactaccc agtagatct tctctctag aagaatcagt
 4621 aggcagctc gaaggagtc gatgtctgt ctgtcttt caaagttctg acacagaaag
 4681 tgatgagcta tcagaagtac ttcaagacag ctgctttta caaataaaat gtgatacaa
 4741 agatgacagt atccctgct ttctggaagt aaaagaagag gatgaaatag tctgcacaca
 4801 acactggcag gatctgtgc ctggacaga actctcagt ctacagacag aggatggctt
 4861 ctggaaactt acaccagaac tgggacttat attaaatct aatacaaat gttgcacag
 4921 ctctcttaa caaaaggca tcaatctct aggtgtaaaa ggaagagaat gtctcttga
 4981 cctaattgcc acaatgctgg tactacagtt tctgcacc aggttggaag aagagggaat
 5041 agtgttcaa tcaatgatga aaatggatga ccttctatt tccaggaata ttccctggg
 5101 ttgtaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc
 5161 tatctgcca cggttgaac tggggaacga ctgggactct gccaccaagc agttgtcgg
 5221 actccagccc ataagcactg tctccctct tcatagagtc ctccattaca gtcaaggcta
 5281 agtcaaatga aactgaattt taaactttt gcctgtctt atgtagaaa taatcaaat
 5341 ataatagata ctataatga aacttatta aggttcatt cagtgtagca attactgtt
 5401 ttaaaaatta agtgaagaa gaattactt aatcaactaa caagcaataa taaatgaaa
 5461 cttaaaat

Figure 9 (continued)

Figure 10

1 ctagaattca gggccgctg aattctaggg ggcgcggcgg cgacggagca ccggcggcgg
 61 caggcgagaga gcattaaatg aaagcaaaag agttaataat ggcaacacgg ctccagaaga
 121 ctctccct gccaaagaaa ctctagatg ccagagacag gactgaaaa agatgcctgt
 181 ggctggagga aaagctaata aggacaggac agaagacaag caagatggta tgccaggaag
 241 gtcatgggcc agcaaaaggg tctctgaatc tgtgaaggcc ttgctgttaa agggcaaac
 301 tcctgtggac ccagagtga cagccaagggt ggggaaggct catgtgtatt gtgaaggaaa
 361 tgatgtctat gatgtcatgc taaatcagac caatctccag ttcaacaaca acaagtacta
 421 tctgattcag ctattagaag atgatgccc gaggaacttc agtgtttgga tgagatgggg
 481 ccgagttggg aaaatgggac agcacagcct ggtggcttgt tcaggcaatc tcaacaaggc
 541 caaggaaatc ttccagaaga aattccttga caaacgaaa aacaattggg aagatcgaga
 601 aaagtttgag aaggtgcctg gaaaatatga tatgtctacag atggactatg ccaccaatac
 661 tcaggatgaa gaggaacaa aaaaagagga atctcttaa tctcccttga agccagagtc
 721 acagctagat ctccgggtac aggagttaaa aaagttgac tgtaatttc aggccatgga
 781 agaaatgatg atggaaatga agtataatac caagaaagcc ccacttggga agctgacagt
 841 ggcacaaatc aaggcaggtt accagtctct taagaagatt gaggattgta ttccggctgg
 901 ccagcatgga cgagctctca tgaagcatg caatgaattc tacaccagga ttccgcatga
 961 ctttggactc ctactctc cactaatccg gacacagaag gaactgtcag aaaaaataca
 1021 attactagag gctttgggag acattgaaat tgctattaag ctggtgaaaa cagagctaca
 1081 aagcccagaa caccattgg accaacacta tagaaaccta cattgtgcct tgcgccct
 1141 tgaccatgaa agttacgagt tcaaaatgat ttccagtag ctacaatcta cccatgctcc
 1201 cacacacagc gactatacca tgaccttgc ggattgttt gaagtggaga aggatggta
 1261 gaaagaagcc ttccagagag accttcataa caggatgctt ctatggcatg gtccaggat
 1321 gagtaactgg gtgggaatct tgagccatgg gcttcgaatt gccaccctg aagctccat
 1381 cacaggttac atgtttggga aaggaatcta ctttgcagac atgtcttcca agagtccaa
 1441 ttactgcttt gcctctgcc taaagaatac aggactgctg ctcttccag aggtagctct
 1501 aggtcagtg aatgaactac tagaggccaa tctaaggcc gaaggattgc ttcaaggtaa
 1561 acatagcacc aaggggctgg gcaagatggc tccagttct gccacttcg taccctgaa
 1621 tgggagtaca gtgccattag gaccagcaag tgacacagga attctgaatc cagatggta
 1681 taccctcaac tacaatgaat atattgtata taacccaac caggtccgta tgcgtacct
 1741 tttaaagggt cagtttaatt tcttcagct gtgtgaatg ttgatctaa ataaaccaga
 1801 gatctgatct tcaagcaaga aaataagcag tgtgtactt gtgaatttg tgatattta
 1861 tgaataaaa actgtacagg tctaaaaaaa aaaaaaaaaa aaaaaaaaaa

//

Figure 11

1 tgggactggt cgcctgactc ggccctgccc agcctctgct tcacccact ggtggccaaa
 61 tagccgatgt ctaatcccc acacaagctc atccccggcc tctgggattg ttgggaattc
 121 tctccctaat tcacgcctga ggctcatgga gaggcttag acctgggact gccctgggag
 181 gcgcacacaa ccaggccggg tggcagccag gacctctccc atgtccctgc ttctctggc
 241 catggctcca aagccgaagc cctgggtaca gactgagggc cctgagaaga agaagggccg
 301 gcaggcagga agggaggagg accccttccg ctccaccgt gaggccctca agccatacc
 361 cgcagagaag cgcataatcc gcgtggatcc aacatgtcca ctacgcagca acccgggac
 421 ccaggtgtat gaggactaca actgcacct gaaccagacc aacatcgaga acaacaaca
 481 caagttctac atcatccagc tgcctcaaga cagcaaccgc ttcttacct gctggaaccg
 541 ctggggccgt gtgggagagg tcggccagtc aaagatcaac cacttcaaa ggctagaaga
 601 tgcaagaag gactttgaga agaaatttcg ggaaaagacc aagaacaact gggcagagcg
 661 ggaccacttt gtgtctacc cgggcaagta cacactatc gaagtacagg cagaggatga
 721 ggcccaggaa gctgtggtga aggtggacag agggccagtg aggactgtga ctaagcgggt
 781 gcagccctgc tcctggacc cagccacgca gaagctatc actaacatct tcagcaagga
 841 gatgtcaag aacacatgg ccctcatgga cctggatgtg aagaagatgc ccctgggaaa
 901 gctgagcaag caacagattg cacggggtt cgaggcctg gaggcgctgg aggaggccct
 961 gaaaggcccc acggatggtg gccaaagcct ggaggagctg tctcacact ttacaccgt
 1021 catcccgac aacttcggcc acagccagcc ccgcccac aattccctg agcttctgca
 1081 ggccaagaag gacatgtgc tgggtctggc ggacatcgag ctggcccagg ccctgcaggc
 1141 agtctctgag caggagaaga cggaggagga ggtgccacac ccctggacc gagactacca
 1201 gcttctcaag tgccagctgc agctgctaga ctctggagca cctgagtaca aggtgataca
 1261 gacctactta gaacagactg gcagcaacca cagggtccct acacttaac acatctggaa
 1321 agtaaaccaa gaaggggagg aagacagatt ccaggccac tccaaactgg gtaatcgaa
 1381 gctgctgtgg catggacca acatggcgt ggtggccgcc atctcacta gtgggctccg
 1441 catcatgcca cattctggtg ggcgtgttg caagggcac tactttgcct cagagaacag
 1501 caagtcagct ggatatgta ttggcatgaa gtgtggggcc caccatgtc gctacatgtt
 1561 cctgggtgag gtggccctgg gcagagagca ccatatcaac acggacaacc ccagcttgaa
 1621 gagccacct cctggcttcg acagtgtcat tgcccaggc cacaccgagc ctgatccgac
 1681 ccaggacact gaggtaggc ttgatggcca gcaagtggg gtgcccagg gccagcctgt
 1741 gccctgccc gagttcagca gctccacatt ctcccagagc gactacctca tctaccagga
 1801 gagccagtgt cgcctgcgt acctgtgga ggtccacctc tgagtggccg ccctgtcccc
 1861 cggggctctg caaggctgga ctgtatctt caatcatct gccatctct ggtacccta
 1921 tatcactct ttttcaag aatacaatac gttgtgta actatagta ccatgctga
 1981 caagatccct gaactatgc ctctaactg aaatttgta ttcttgaca catctgcca
 2041 gtccctctcc tcccagcca tgtaaccag cattgactc ttacttgta taagggcagc
 2101 ttttataggt tccacatgta agtgagatca tgcagtgtt gtcttctgt gcctggctta
 2161 ttctactcag cataatgtc accgggtca ccatgttt cataaatgac aagatttct
 2221 ccttaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa

U.S. Patent

Oct. 14, 2014

Sheet 14 of 20

US 8,859,562 B2

Figure 12

```

1  cgaagatggc ggcgctcgct cgtctcagc atcatcacca ccatcatcaa caacagctcc
61  agcccccccc aggggcttca gcgcgcgcgc cggccactcc tccccactc agccctggcc
121  tggccccggg gaccacccca gctctccca cggccagcgg cctggcccc ttcgctccc
181  cgcggcacgg cctagcgtg ccggaggggg atggcagtcg ggatccgccc gacaggcccc
241  gatccccgga ccgggttgac ggtaccagct gttgcagtac caccagcaca atctgtaccg
301  tcgccgcgcg tcccggtggt ccagcggttt ctacttcate tgcgcgtggg gtgcctcca
361  acccagccgg cagtggcagt aacaattcac cgtcgtcttc ttcttcccc acttcttctt
421  catcttcttc tccatctctc cctggatcga gcttggcggg gagccccgag gcggccggag
481  tttagcagcac agcaccactg gggcctgggg cagcaggacc tgggacaggg gtcccagcag
541  ttgagcgggg cctacgggaa ctgctggagg cctgtcgcaa tggggacgtg tcccgggtaa
601  agaggctggg ggacggcgca aacgtaaatg caaaggacat ggccggcccg aagtcttctc
661  ccttcgactt cgttcgaggt ttggaaggga aggatgttgt agaacttta ctacagatg
721  gtgctaatgt ccacgctcgt gatgatggag gtctcatccc gcttcataat gctgttctt
781  ttggccatgc tgaggttggt agtctgttat tgtgccagg agctgatcca aatgccaggg
841  ataactggaa ctatacacct ctgcatgaag ctgctattaa agggaagatc gatgtgtgca
901  ttgtgtgtgt gcagcacgga gctgacccaa acattcggaa cactgatggg aatcagcccc
961  tggacctggc agatccttca gcaaaaagctg tccttacagg tgaatacaag aaagacgaac
1021  tcttagaagc tgctaggagt ggtaaatgaag aaaaactaat ggctttactg actcctctaa
1081  atgtgaattg ccatgcaagt gatggcgcaa agtcgactcc tttacatcta gcagcgggct
1141  acaacagagt tcgaatagtt cagcttcttc ttacagatgg tgcgtatgtt catgcaaaag
1201  acaaaaggtg acttgtgctt ctccataatg catgttcata tggacattat gaagtcacag
1261  aactgctact aaagcatgga gcttgtgtta atgccatgga tctctggcag tttactccac
1321  tgcacgaggg tgcttccaaag aaccgtgtag aagtctgtct tttgttactt agccatggcg
1381  ctgactcctac gttagtcaac tgccatggca aaagtgtgtt ggatatggct ccaactccgg
1441  agcttaggga gagattgact tatgaattta aaggtcattc tttactacaa gcagccagag
1501  aagcagactt agctaaagt aaaaaaacac tcgctctgga aatcattaat ttcaaacac
1561  cgcagctctc tgaacacgca ctgcaactgt ctgtggcctc tctgcacccc aaacgtaaac
1621  aagtgcacga attgttactt agaaaaggag caaatgttaa tgaaaaaaat aaagatttca
1681  tgactcccc gcattgttga gccgaaagag cccataatga tgcattggaa gttctgcata
1741  agcatggcgc caagatgaat gcactggaca ccttgggtca gactgctttg catagagccg
1801  ccctagcagg ccacttcgag acctggcgc ccttgcgtgag ttacggctct gacccctcca
1861  tcatctcctt acaaggcttc acagcagcac agatgggcaa tgaagcagtg cagcagattc
1921  tgagtgtgag ttacggctct gacccctcca tcatctcctt acaaggcttc acagcagcac
1981  agatgggcaa tgaagcagtg cagcagattc tgagtgggtc ttcgtagata gtgatcattc
2041  tacttcagcc ttaattggtga tcttgagacg ggaagattta gaaggaaatc tatccagcat
2101  gtcttcactg tcaacatgaa gactacacct atactgaact ctgatgttga ttactgaact
2161  tttagagcat ctaaaagctg agacttggaa actgtgaagc aactttgcag ctctcaaaat
2221  gtgaattgta gagacttaga gggccggcat tccacgcctt tacacttcgc agcaggctac
2281  aacagagtac acctatacgt acttctgatg ttgattatcg actcttagag gcactctaaag
2341  ctgggagactt ggaaactgtg aagcaacttt gcagctctca aaatgtgaat tgtagagact
2401  tagagggcgg gcattccacg ccttactact tgcagcagg ctacaaccgc gtgtctgttg
2461  tagagtacct gctacaccac ggtgcccgat tccatgccaa agacaagggt ggtctgtgtg
2521  cccttcataa tgcctgttca tatggacact atgaggtggc tgagctttta gtaaggcatg
2581  gggcttctgt caatgtggcg gacttatgga aatttaccct tctccatgaa gcagcagcta
2641  aaggaaagta tgaatctgc aagctccttt taaaacatgg agcagatcca actaaaaaga
2701  acagagatgg aaatacacct ttggatttgg taaaggaagg agacacagat attcaggact
2761  tactgaaagg ggatgctgct ttgttgatg ctgccaaaga gggctgcttg gcaagagtgc
2821  agaagctctg taccocagag aatatcaact gcagagacac ccagggcaga aattcaacc
2881  ctctgcacct ggcagcaggc tataataacc tggaaagtag tgaatatctt ctagagcatg
2941  gagctgatgt taatgcccg gacaagggtg gtttaattcc tcttcataat gggcatctt
3001  atgggcatgt tgacatagcg gctttattga taaaatacaa cactgtgtga aatgcaacag
3061  ataagtgggc gtttactccc ctccatgaag cagccagaa aggaaggacg cagctgtgcg
3121  cctctctcct agcgcaggtg gcagacccca ccatgaagaa ccaggaaggc cagacgcctc
3181  tggatctggc aacagctgac gatatcagag ctttgctgat agatgccatg ccccagagg
3241  ccttacctac ctgtttttaa cctcaggcta ctgtagtgag tgcctctctg atctcaccag
3301  catccacccc ctctgcctc tcggctgcca gcagcataga caacctcact ggcccttag
3361  cagagtggc cgtaggagga gctccaatg caggggatgg cgcgcgggga acagaaagga
3421  aggaaggaga agttgctggt cttgacatga atatcagcca atttctaaaa agccttggcc
3481  ttgaaacacct tcgggatata tttgaaacag aacagattac actagatgtg ttggctgata
3541  tgggtcatga agagtgaag gaaataggca tcaatgcata tgggcaccgc cacaatttaa
3601  tcaaaggagt agaaagactc ttagggtgac aacaaggcac caatccttat ttgactttt
3661  actgtgttaa tcagggaacg atttgcctgg atcttgcctc agaagataaa gaatatcagt
3721  cagtggagaa agagatgcaa agtactattc gagaacacag agatgggtgt aatgctggcg
3781  gcacttcaa cagatacaat gtcatctgaa ttcaaaaagt tgtcaacaag aagttgaggg
3841  agcgggtctg ccaccgacag aaggaggtgt ctgaggagaa tcacaacct cacaatgagc

```

```
3901 gcatgttgtt tcatggttct cctttcatta atgccattat tcataaaggg tttgatgagc
3961 gacatgcata cataggagga atgtttgggg ccgggattta ttttctgaa aactcctcaa
4021 aaagcaacca atatgtttat ggaattggag gaggaacagg ctgccctaca cacaaggaca
4081 ggatcatgcta tatatgtcac agacaaatgc tcttctgtag agtgaccctt gggaaatcct
4141 ttctgcagtt tagcaccatg aaaatggccc acgcgcctcc agggcaccac tcagtcatg
4201 gtagaccgag cgtcaatggg ctggcatatg ctgaatatgt catctacaga ggagaacagg
4261 catacccaga gtatcttatt acttaccaga tcatgaagcc agaagcccct tcccagaccg
4321 caacagccgc agagcagaag acctagttaa tgcctgctgg tgaaggccag atcagatttc
4381 aacctgggac tggattacag aggattgttt ctaataacaa catcaatatt ctagaagtc
4441 ctgacagcct agaaataagc tgtttgtctt ctataaagca ttgctatagt g
```

Figure 12 (continued)

Figure 13

1 cgcgcgcct cgtagccga aacctgccca gccggtgcc ggccactgcg cacgcgcggg
 61 acgacgtcac gtgcgtccc ggggctggac ggagctggca ggaggggcct tgcagcttc
 121 cggcgcccg tctttcagg acccggaagg cggattcgcg ctgcctcgc cgcgcgggg
 181 cagccggggg gcaggagacc cagcagggg cgcgcgtggg cgcggccatg ggactgcgc
 241 ggatccggtg acagcaggga gccaaagcgc cggggccctg agcgcgtctt ctccggggg
 301 cctcgcctc ctgctcgcg ggcggggct cctgctcgg ttgctggcg tttgctggc
 361 tgtggcgcg gccaggatca tgcgggicg ccgctgcgc ggcgggggag cggcctgcg
 421 gagcgcccg gccgaggcg tggagccgg cggcgagag ctgttcgagg cgtgccgaa
 481 cggggacgtg gaacgagta agaggtggt gacgcctgag aaggtgaaca gccgcgac
 541 ggccggcagg aaatccacce cgtgcactt cggcgaggt ttgggggga aagacgtat
 601 tgaatattg cttcagaatg gtgcaaatg ccaagcacgt gatgatggg gccttattc
 661 tctcataat gcattgctt ttggtcagc tgaagtagc aatctctt tgcgacatg
 721 tgcagacccc aatgctcag ataattgaa ttactctt ctccatgaag ctgcaataa
 781 aggaaagatt gatgtttgca ttgtctgtt acagatgga gctgagcaa ccatccgaa
 841 tacagatgga aggacagcat tggatttagc agatccatc gccaaagcag tgcctactg
 901 tgaatataag aaagatgaac tctagaaag tccaggagt ggcaatgaag aaaaatgat
 961 ggctctact acaccattaa atgtcaactg ccacgcaagt gatggcagaa agtcaactc
 1021 attacattg gcagcaggat ataacagat aaagattga cagctgttac tgcacatgg
 1081 agctgatgc catgctaaag ataaaggtga tctggtacca ttacacaatg cctgttcta
 1141 tggctattt gaagtaactg aacttttgg caagcatggt gcctgtgta atgcaatga
 1201 ctgtggcaa ttcactctc ttcagagc agcttctaag aacagggtg aagtatgtc
 1261 tcttcttta agttatggtg cagaccaac actgctaat tgcacaata aaagtgtat
 1321 agacttggt cccacaccac agttaaaga aagattagca tatgaatga aaggccactc
 1381 gttgtgcaa gctgcagag aagctgatgt tactgaac aaaaacatc tctcttgga
 1441 aatggtgaat tcaagcatc ctcaaacaca tgaacagca ttgcattgt ctgctgcatc
 1501 tccatatccc aaaagaagc aatatgtga actgttcta agaaaaggag caaacatcaa
 1561 tgaagact aaagaattct tgactctct gcacgtggca tctgagaaag ctcataatga
 1621 tgtgttgaa gtagtggtga aacatgaagc aaaggtaat gctctggata atcttggtc
 1681 gacttctta cacagagctg catattgtg tcatctaaa acctgcgc tactcctgag
 1741 ctatgggtgt gatctaaca ttatatccct tcagggttt actgcttac agatgggaaa
 1801 tgaatatga cagcaactc tcaagaggg tatctatta ggtaatcag aggcagacg
 1861 acaattgctg gaagtgcaa aggtggaga tgcgaaact gtaaaaaaac tgttactgt
 1921 tcagagtgtc aactgcagag acattgaagg gcgtcagct acaccattc atttgcagc
 1981 tgggtataac agagtgtccg tgggtgaata tctgtacag catggagctg atgtcatgc
 2041 taaagataaa ggaggccttg taccttgca caatgcatgt tctatggac attatgaat
 2101 tgcagaactt ctgtttaa acatggagcgt agttaatga gctgattat ggaaattac
 2161 acctttacat gaagcagcag caaaaggaaa atatgaaatt tgcaacttc tgcctcagca
 2221 tggtcagac cctacaaaaa aaaacaggga tggaaatact cctttggatc ttgttaaaga
 2281 tggagataca gatattcaag atctgcttag gggagatgca gctttgctag atgtgccaa
 2341 gaagggtgt ttaccagag tgaagaagt gtctctct gataatgtaa atggccgca
 2401 taccacaggc agacattcaa cactttaca tttagcagct ggtataata attagaagt
 2461 tgcagagtat ttgtacaac acggagctga tgtgaatgcc caagacaaag gaggacttat
 2521 tctttacat aatgcagcat ctacgggca ttagatgta gcagctctac taataaagta
 2581 taatgcatgt gtcaatgca cggacaatg gctttcaca cctttgcac aagcagccca
 2641 aaaggagca acacagctt gtgcttgtt gtagcccat ggagctgacc cgactctaa
 2701 aatcaggaa ggacaacac ctttagattt agttcagca gatgatgtca gcgtctct
 2761 gacagcagcc atgccccat ctgctctgcc ctctgttac aagcctcaag tgcataatg

2821 tgtgagaagc ccaggagcca ctgcagatgc tctctcttca ggtccatcta gcccataag
 2881 cctttctgca gccagcagtc ttgacaactt atctgggagt tttcagaac tgtcttcagt
 2941 agttagtcca agtggacag aggggtcttc cagtttgag aaaaaggagg ttccaggagt
 3001 agattttagc ataactcaat tcgtaaggaa tcttgactt gacaccta tggatatatt
 3061 tgagagagaa cagatcaact tggatgtatt agttgagatg gggcacaagg agctgaagga
 3121 gatttgaatc aatgcttatg gacataggca caaactaatt aaaggagtcg agagacttat
 3181 ctccggacaa caaggctta acccatattt aacttgaac acctctggta gtggaacaat
 3241 tcttatagat ctgtctctg atgataaaga gtttcagtct gtggagggaag agatgcaaag
 3301 tacagttcga gacacagag atggaggcca tgcagggtga atctcaaca gatacaatat
 3361 tctcaagatt cagaagggtt gtaacaagaa actatgggaa agatacactc accggagaaa
 3421 agaagtttct gaagaaaacc acaaccatgc caatgaacga atgctatttc atgggtctcc
 3481 ttttgaat gcaattatcc acaaaggctt tgatgaagg catgctaca taggtggtat
 3541 gtttgagct ggcatttatt ttgctgaaaa ctctccaaa agcaatcaat atgtatatgg
 3601 aattggagga ggtactgggt gtccagtcca caaagacaga tctgtttaca ttgccacag
 3661 gcagctgctc ttttccggg taacctggg aaagtcttc ctgcagtcca gtgcaatgaa
 3721 aatggcacat tctctccag gtcacactc agtcactggt aggccagtg taaatggcct
 3781 agcattagct gaatafctta ttacagagg agaacaggct tctctgagt atttaattac
 3841 ttaccagatt atgaggcctg aaggatggt cgtatggata atagtattt taagaaacta
 3901 attccactga acctaaaac atcaaagcag cagtggcctc tacgtttac tctttgctg
 3961 aaaaaaaac atctgcccc caggcctgtg gcaaaaggat aaaaatgtga acgaagtta
 4021 acattctgac ttgataaagc ttaataatg tacagtgtt tctaatatt tctgtttt
 4081 tcagcacttt aacagatgcc attccagggt aaactgggtt gctgtacta aattataaac
 4141 agagttaact tgaacctttt atatgttatg cattgattct aacaaactgt aatgccctca
 4201 acagaactaa tttactaat acaatactgt gttctttaa acacagcatt tacactgaat
 4261 acaatttcat ttgtaaaact gtaataaga gctttgtac tagccagta tttattaca
 4321 ttgctttgta atataaatct gttttagaac tgcagcgggt tacaaaattt ttcatatgt
 4381 attgtcactc tatacttcat ctacatcgt catgattgag tgatctttac atttgattcc
 4441 agaggctatg ttcagttgtt agttgggaaa gatlgagta tcagattaa ttgccgatg
 4501 ggagccttta tctgtacta gaaatcttc tcatthaaga acttatgaat atgtgaaga
 4561 ttaatttgt gataaccttg tatgtatgag acacattcca aagagctcta actatgatag
 4621 gtcctgatta ctaaagaagc ttcttactg gcctcaattt ctagcttcca tgttgaaaa
 4681 tttctgcag tcttctgtg aaaattagag caaagtcctc ctgttttta gagaaactaa
 4741 atcttgctgt tgaacaatta ttgtgttctt tcatggaac ataagtagga tgttaacatt
 4801 tccagggttg gaagggtaat cctaaatcat tcccaatct attctaatta ccttaaatct
 4861 aaaggggaaa aaaaaatca caaacaggac tgggtagttt ttatcctaa gtatatattt
 4921 tctgttctt ttacttgggt ttattgctg tatttatagc caatctatac atcatgggta
 4981 aacttaacce agaactataa aatgtagtgt ttccagtcce ctccaggcct cctgaatggg
 5041 caagtgcagt gaaacagggt ctctctgctc ctgggttttc tctccatgat gttatgccc
 5101 attgaaata tctgtcagt ttgtgcacca tatggtgacc acgctgtgc tcagtttggc
 5161 agctatagaa ggaaatgctg tccataaaa tgcacccct attctaata taacactctt
 5221 ttccagggaag catgcttaag catcttgta cagagacata catccattat ggcttgccaa
 5281 tctcttttat ttgtgactc tagctccctt caaagtcgag gaaagatctt tactcacta
 5341 atgaggacat tcccatac tgtctgtacc agttcacctt tatttacgt ttattcagt
 5401 ctgtaatta actggccctt tgcagtaact tttacataaa gtgctagaaa atcatgttc
 5461 ttgtctgag taagagttaa tcagagtaag tgcatttctg gagttgttc tgtatgtaa
 5521 attatgatca ttatttaaga agtcaaatcc tgatcttgaa gtgttttta tacagctctc
 5581 taataattac aaatatccga aagtcatttc ttggaacaca agtgagatg gccaaattt
 5641 atatgaattt ttcaattat ctaagcttcc aggttttata attagaagat aatgagagaa
 5701 ttaattgggt ttatatttac attatctctc aactatgtag cccatattac tcacctatg
 5761 agtgaatctg gaattgctt tcatgtgaaa tcatgtggt ctatgagttt acaatactgc

Figure 13 (continued)

U.S. Patent

Oct. 14, 2014

Sheet 18 of 20

US 8,859,562 B2

5821 aaactgtgtt atttatcta aaccattgct taatgagtgt gttttccat gaatgaatat
5881 accgtgggtc atatgttagc atggcagcat ttcagatag ctttttgttt gtggggaagt
5941 tggggttttg gggggagggg gagtattagt acgttgcacg gaatagccta cttataatg
6001 atgggaatgc ttttctttt gtttgggat tttttttt gaagtgaat ttaactttt
6061 gtgccagtag tactattata cccatcttca gtgtcttact tgtactgtat caaatccat
6121 accctcattt aattctaat aaaactgtc acttgtaaaa aaaaaaaaaa aaaaaaaaaa
6181 aaaaaaaaaa

Figure 13 (continued)

Figure 14

1 cccccccca gccccggggg cagggaaagc ctaaattacg gaattaccgc gagcaaggag
 61 cgcgggaatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tgatgggaat
 121 ctttgcaaat tgtatcttct gtttgaaagt gaagtactta cctcagcagc agaagaaaaa
 181 gctacaaact gacattaagg aaaatggcgg aaagtttcc ttctgttaa atcctcagt
 241 cacacatata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca
 301 aaagaaccac gticatatgg caaaccaga ttttatatgg aaatctatca gagaaaagag
 361 actcttggat gtaaagaait atgacctta taagccctg gacatcacac cactcctga
 421 tcagaaggcg agcagttctg aagtgaaac agaaggtcta tgcccggaaca gtgccacaga
 481 ggaggaagac actgtggaac tctgaggtt tggatgcag aatgtgaaa ttctcatct
 541 tctcaagat tttgaagttg caaaatataa cacttgag aaagtgggaa tggagggagg
 601 ccaggaagct gtgggtggg agcttcagt ttcggggac tccagggact gtccttct
 661 gatactctca cacttctcc tggatgatgg catggagact agaagacagt ttgtataaa
 721 gaaaacctct gaagatgcaa gtgaatacti tgaattac attgaagaac tgaagaaca
 781 aggatttcta ctaagagaac atttcacacc tgaagcaacc caattagcat ctgaacaatt
 841 gcaagcattg ctttggagg aagtcagaa tcaagcact ctgagccaag aggtgagcga
 901 tttagtagag atgatttggg cagaggccct gggccacctg gaacacatgc ttctcaagcc
 961 agtgaacagg attagcctca acgatgtgag caaggcagag gggattctcc ttctagtaaa
 1021 ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagtitta
 1081 cagactgata cctcacaag gcacaatgcc caaagaagtg aacctgggac tattggctaa
 1141 gaaagcagac ctctgccagc taataagaga catggtaat gtctgtgaaa ctaatttgc
 1201 caaaccacac ccaccatccc tggccaaata ccgagctttg aggtgcaaaa ttgagcatgt
 1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gtttgcaga atcatcacag
 1321 taagagccca gtggatgtct tgcagatatt tagagtggc agagtgaatg aaaccacaga
 1381 gttttgagc aaacttgga atgtgaggcc ctgttgcatt ggttctctg taaaaacat
 1441 cgtgggaatc ttgtgtcag gttgtcttt acccaaagta gtggaagatc gtgtgtgca
 1501 aagaacagac gtcggaaacc ttggaagtgg gatttattc agtgattcgc tcagtacaag
 1561 tatcaagtac tcacaccgg gagagacaga tggcaccaga ctcctgtcga ttgtgacgt
 1621 agccctcgga aagtgtatgg acttacatga gaaggactti ccttaactg aagcaccacc
 1681 aggtacgac agtgtgcatg gagtttcaca aacagcctct gtcaccacag actttgagga
 1741 tgatgaattt gtgtctata aaaccaatca ggttaaatg aaatatatta ttaatttct
 1801 catgcttga gatcagataa aggacttca tctagtgtat catactgaat tagaggaata
 1861 cagacctgag tttcaaat ttcaaaagt tgaagattac cagttaccag atgcaaac
 1921 ttccagcagc accaaggccg gctccagga tgcctctggg aacttggtc ctctggagga
 1981 tgtccacatc aaaggagaa tcatagacac ttagcccag gtcattgtt ttacacata
 2041 cacaataaaa agtcacgtgc ccattgagc aaaaatatac tticcttgg atgacaaggc
 2101 cgctgtgtgt ggttcgaag cttcatcaa tgggaagcac atagtggag agattaaaga
 2161 gaaggaagaa gccagcaag agtacctaga agcgtgacc cagggccatg gcgcttacct
 2221 gatgagtcag gatgtccgg acgtttttac tgaagtgti ggaaacttac cccctaaggc
 2281 taaggttctt ataaaaatta cctacatcac agaactcagc atcctgggca ctgttggtgt
 2341 cttttcatg cccgccaccg tagcaccctg gcaacaggac aaggcttga atgaaaacct
 2401 tcaggatata gtagagaaga ttgtataaa agaaatagga acaagcaaa gtttcttct
 2461 gactatgtct attgagatgc cgtatgtgat tgaattcatt ttcatgata cacatgaact
 2521 gaaacaaaag cgcacagact gcaaaagtgt cattagcacc atggaaggca gtccttaga
 2581 cagcagtgga tttctctcc acatcggtt gtctgtgcc tatctccaa gaatgtgggt
 2641 tgaaaaacat ccagaaaaag aaagcgagc ttgcatgcti gttttcaac ccgatctga
 2701 tgtcgacctc cctgacctag ccagtgaag cgaagtgaat atttgtctt actgtccag

2761 ttccatggag ggtgtgacat tcttgaagc caagcaaatc accttgcattg cgtgtctct
 2821 ggtgggtgag aagcagaaag taaatattat ccagttcggc acaggttaca aggagctatt
 2881 ttctatcct aagcatatca caagcaatac cacggcagca gagttcatca tgtctgccac
 2941 acctaccatg gggaaacacag acttctggaa aacactccga tatcttagct tattgtacce
 3001 tgctcgaggg tcacggaaca tctctctggt gctgtatggg cactccagg atgagagcct
 3061 gacattacag ctctgtaaga ggagccgcc gcacaccagg ttatccctt gcggtatcgg
 3121 ttctacagca aatcgtcacg tcttaaggat ttgtccag tgggtgccc gagtattga
 3181 atattttaat gcaaaatcca agcatagtgt gagaaaacag atagaagacc aatgaccag
 3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc
 3301 gcccgaggcc ctgcaggccc cagcccagggt gccatccttg ttctgcaatg atcgactcct
 3361 tgtctatgga ttactctc actgcacaca agcaactctg tgtgactaa tcaagagaa
 3421 agaatttgt acaatggtgt cgactactga gcttcagaag acaactggaa ctatgalcca
 3481 caagctggca gcccgagctc taatcagaga ttatgaagat ggcattctc acgaaatga
 3541 aaccagtcct gagatgaaaa acaaacctt gaaatctctg attattaac tcagtaaga
 3601 aaactctc ataacacaat ttacaagctt tgggcagtt gagaaaagg atgagaatga
 3661 gtgcctttt ctgatattc caaaagtgc tgaactatt gccaaagaag atlagactt
 3721 cctgccctac atgagctggc agggggagcc ccaagaagcc gtcaggaacc agtctcttt
 3781 agcatcctct gagtggccag aattacgtt atccaaacga aaacatagga aaattccatt
 3841 ttccaaaaga aaaatggaat tctcagcc agaagttct gaagatttg aagaggatgg
 3901 cttaggtgta ctaccagctt tcatcaaaa ttggaactg ggaggtgtgg aaaagctatt
 3961 ggaattaaat tggacagagt catgtaaac aacagcaact gaaccactat ttaagaaat
 4021 cagtcctgg gaaacatca ctctagctt ttctctatt ttggctccgg ccgttggtc
 4081 ctactctacc ccgactacc gcgctcacag tctgtctcc ttgtcttg cctcatatcg
 4141 tcaggtagct agttcggtt cagctgtcc tccagacag ttgatgcat ctcaattcag
 4201 ccaagccct gtgcctggca ctgtgtga ctggaacca cagtcggcgt ctgtccac
 4261 aggacctcc cagaacctc ctctgcacc ctattgtgc attgtttt caggagctc
 4321 attaatctt gcacagctc ctccactgca acatctgga ggccttacta ccaggcctc
 4381 tgctggcacc ttccctgagc tggattctc ccagcttcat ttctcttc ctacagacc
 4441 tgatccatc agaggtttg ggtcttaca tccctctgt tactctctt ttacttca
 4501 acctccgca gcctcttga ctgccaacct taggtgcca atggcctctg cttaactga
 4561 ggctcttgc agtcagtcgc ggaactcccc agtagatct tgtctctag aagaatcagt
 4621 aggagctct gaaggagtc gatgtctgt cttgtctt caaagtctg acacagaaag
 4681 tgatgagctc tcagaagtc ttcaagacag ctgctttta caaataaagt gtgatacaaa
 4741 agatgacagt atccctgtt ttctggaatt aaaagaagag gatgaaatag tgtgcacaca
 4801 aactggcag gatgtgtgc ctggacaga actctcagt ctacagacag aggatggctt
 4861 ctggaacct acaccagaac tgggacttat attaatctt aalacaaatg gttgcacag
 4921 ctctctaaa caaaaaggca ttcaatctt aggtgtaaaa ggaagagaat gtctctgga
 4981 cctaattgcc acaatgctg tactacagtt tatctgacc aggttgaaa aagagggaat
 5041 agtgtaaaa tcaatgatga aatggatga cctctctt tccaggaata ttccctgggc
 5101 ttgtaggca ataaagcaag caagtgaatg gtaagaaga actgaaggac agtaccatc
 5161 tatctgcca cggttgaac tgggaacga ctgggactct gccaccaagc agttgtggg
 5221 actccagccc ataagcactg tgcctctct tcatagagtc ctccattaca gtaaggcta
 5281 agtcaaatga aactgaatt taaactttt gcagctctt atgtagaaa taatcaaatg
 5341 ataatagata attataatga aacttcta aggttctt cagtgagca attactgtt
 5401 ttaaaaatta agtgaagaa gaattactt aatcaactaa caagcaataa taaatgaa
 5461 cttaaaataa aaaaaaaaaa aaaaaaaaaa

Figure 14 (continued)

US 8,859,562 B2

1

USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER

This invention relates to the use of an agent that inhibits the activity of an enzyme which mediates the repair of DNA strand breaks in the treatment of certain forms of cancer in particular breast cancer.

Homologous recombination (HR) has been shown to play an important role in repair of damage occurring at DNA replication forks in mammalian cells (2). Thus, cells deficient in HR show retarded growth and exhibit higher level of genetic instability. It is believed that genetic instability due to loss of HR repair in human cancers significantly contributes to the development of cancer in these cells (1).

Post transcriptional modification of nuclear proteins by poly(ADP-ribosyl)ation (PARP) in response to DNA strand breaks plays an important role in DNA repair, regulation of apoptosis, and maintenance of genomic stability.

Poly(ADP-ribose) Polymerase (PARP-1) is an abundant nuclear protein in mammalian cells that catalyses the formation of poly(ADP-ribose) (PAR) polymers using NAD⁺ as substrate. Upon DNA damage, PARP-1 binds rapidly to a DNA strand break (single strand or double strand) and catalyses the addition of negatively charged PAR chains to itself (automodification) and other proteins (see [3, 4] for reviews). The binding of PARP-1 to DNA strand breaks is believed to protect DNA lesions from further processing until PARP-1 is dissociated from the break by the accumulated negative charge resulting from PAR polymers (5,6).

Although PARP-1 has been implicated in several nuclear processes, such as modulation of chromatin structure, DNA replication, DNA repair and transcription, PARP-1 knockout mice develop normally (7). Cells isolated from these mice exhibit a hyper recombination phenotype and genetic instability in the form of increased levels of SCE, micronuclei and tetraploidy (8-10). Genetic instability may also occur in these PARP-1 knockout mice through telomere shortening, increased frequency of chromosome fusion and aneuploidy (11), although all of these results could not be repeated in another set of PARP-1 knock-out mice (12). In the former mice knockout, PARP-1 null mutation rescue impaired V(D)J recombination in SCID mice (13).

These results support the view suggested by Lindahl and coworkers that PARP-1 has a protective role against recombination (5). They proposed that binding of PARP-1 to DNA strand breaks prevents the recombination machinery from recognizing and processing DNA lesions or, alternatively, that the negative charges accumulated following poly ADP-ribosylation repel adjacent recombinogenic DNA sequences. Only the latter model is consistent with inhibition of PARP-1 itself and expression of a dominant negative mutant PARP-1, inducing SCE, gene amplification and homologous recombination (HR [14-18]).

Studies based on treating cells with PARP inhibitors or cells derived from PARP-1 or PARP-2 knockout mice indicate that the suppression of PARP-1 activity increases cell susceptibility to DNA damaging agents and inhibits strand break rejoining (3, 4, 8-11, 19, 20, 47).

Inhibitors of PARP-1 activity have been used in combination with traditional anti-cancer agents such as radio therapy and chemotherapy (21). The inhibitors were used in combination with methylating agents, topoisomerase poisons and ionising radiations and were found to enhance the effectiveness of these forms of treatment. Such treatments, however,

2

are known to cause damage and death to non cancerous or "healthy" cells and are associated with unpleasant side effects.

There is therefore a need for a treatment for cancer that is both effective and selective in the killing of cancer cells and which does not need to be administered in combination with radio or chemotherapy treatments.

The present inventors have surprisingly found that cells deficient in homologous recombination (HR) are hypersensitive to PARP inhibitors as compared to wild type cells. This is surprising since PARP-1 knockout mice live normally thereby indicating that PARP-1 is not essential for life. Thus, it could not be expected that cells would be sensitive to PARP inhibition.

According to a first aspect of the invention there is provided the use of an agent that inhibits the activity of an enzyme that mediates the repair of DNA strand breaks in the manufacture of a medicament for the treatment of diseases that are caused by a genetic defect in a gene that mediates homologous recombination.

In a further aspect the invention provides a method of treatment of a disease or condition in a mammal, including human, which is caused by a genetic defect in a gene which mediates homologous recombination, which method comprises administering to the mammal a therapeutically effective amount of an agent which inhibits the activity of an enzyme which mediates repair of DNA strand breaks or other lesions present at replication forks.

In a preferred aspect said enzyme is PARP. In a further preferred aspect said agent is a PARP inhibitor or an RNAi molecule specific to PARP gene.

In a further preferred aspect, the use is in the treatment of cancer.

Preferably the medicament is a pharmaceutical composition consisting of the PARP inhibitor in combination with a pharmaceutically acceptable carrier or diluent.

The specific sensitivity of HR defective tumours to PARP-1 inhibition means that normally dividing cells in the patient will be unaffected by the treatment. Treatment of HR defective cancer cells using a PARP inhibitor also has the advantage that it does not need to be administered as a combination therapy along with conventional radio or chemotherapy treatments thereby avoiding the side effects associated with these conventional forms of treatment.

A genetic defect in a gene which mediates homologous recombination may be due to a mutation in, the absence of, or defective expression of, a gene encoding a protein involved in HR.

In a further aspect, the invention further provides the use of a PARP inhibitor in the manufacture of a medicament for inducing apoptosis in HR defective cells.

In another aspect the invention provides a method of inducing apoptosis in HR defective cells in a mammal which method comprises administering to the mammal a therapeutically effective amount of a PARP inhibitor.

By causing apoptosis in HR defective cells it should be possible to reduce or halt the growth of a tumour in the mammal.

Preferably, the HR defective cells are cancer cells.

Cancer cells defective in HR may partially or totally deficient in HR. Preferably the cancer cells are totally deficient in HR.

The term "cancer" or "tumour" includes lung, colon, pancreatic, gastric, ovarian, cervical, breast or prostate cancer. The cancer may also include skin, renal, liver, bladder or cerebral cancer. In a preferred aspect, the cancer is in a mammal, preferably human.

US 8,859,562 B2

3

The cancer to be treated may be an inherited form of cancer wherein the patient to be treated has a familial predisposition to the cancer. Preferably, the cancer to be treated is gene-linked hereditary cancer. In a preferred embodiment of the invention the cancer is gene-linked hereditary breast cancer.

In a preferred aspect, the PARP inhibitor is useful in the treatment of cancer cells defective in the expression of a gene involved in HR. Genes with suggested function in HR include XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Eme1, DDS1, BARD (see (2, 3, 5, 22-28) for reviews).

A gene involved in HR may be a tumour suppressor gene. The invention thus provides for the treatment of cancer cells defective in the expression of a tumour suppressor gene. Preferably, the tumour suppressor gene is BRCA1 or BRCA2.

Breast cancer is the most common cancer disease among women in the Western world today. Certain families have strong predisposition for breast cancer, which is often owing to an inherited mutation in one allele of either BRCA1 or BRCA2. However, these patients still maintain one functional allele. Thus, these patients develop normally and have no phenotypic consequence from this mutation. However, in one cell, the functional allele might be lost, making this cell cancerous and at the same time deficient in homologous recombination (HR). This step is critical for the onset of a tumour (1).

The present inventors have surprisingly found that BRCA2 deficient cells are 100 times more sensitive to the cytotoxicity of the PARP inhibitor, NU1025, than wild type cells.

Thus in a preferred aspect, the invention provides the use of a PARP inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in HR, e.g due to the loss of BRCA1 and/or BRCA2 expression.

The cancer cells to be treated may be partially or totally deficient in BRCA1 or BRCA2 expression. BRCA1 and BRCA2 mutations can be identified using multiplex PCR techniques, array techniques (29, 30) or using other screens known to the skilled person.

PARP inhibitors useful in the present invention may be selected from inhibitors of PARP-1, PARP-2, PARP-3, PARP-4, tankyrase 1 or tankyrase 2 (see 31 for a review). In a preferred embodiment, the PARP inhibitor useful in the present invention is an inhibitor of PARP-1 activity.

PARP inhibitors useful in the present invention include benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinoline derivatives (e.g. 2-(4-hydroxyphenyl)benzimidazole-4-carboxamide (NU1085), 8-hydroxy-2-methylquinazolin-4-[3H]one (NU1025); 6(5H)phenanthridinone; 3 aminobenzamide; benzimidazole-4-carboxamides (BZ1-6) and tricyclic lactam indoles (TII-5) [32]. Further inhibitors of PARP may be identified either by design [33] or the novel FlashPlate assay [34].

The PARP inhibitor formulated as a pharmaceutical composition may be administered in any effective, convenient manner effective for targeting cancer cells including, for instance, administration by oral, intravenous, intramuscular, intradermal, intranasal, topical routes among others. Carriers or diluents useful in the pharmaceutical composition may include, but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.

4

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion. The inhibitor may be administered directly to a tumour or may be targeted to the tumour via systemic administration.

A therapeutically effective amount of the inhibitor is typically one which is sufficient to achieve the desired effect and may vary according to the nature and severity of the disease condition, and the potency of the inhibitor. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease.

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be up to 100 mg/kg, for example from 0.01 mg/kg to 50 mg/kg body weight, typically up to 0.1, 0.5, 1.0, 2.0 5.0, 10, 15, 20 or 30 mg/kg body weight. Ultimately, however, the amount of inhibitor administered and the frequency of administration will be at the discretion of a physician.

A therapeutic advantage of using PARP inhibitors to treat cancer cells is that only very low doses are needed to have a therapeutic effect in treating cancer thereby reducing systemic build up of the inhibitors and any associated toxic effects.

A preferred aspect of the invention provides an agent which is an inhibitory RNA (RNAi) molecule.

A technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding sequence of the gene which is to be ablated.

Preferably said RNAi molecule is derived from the nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

- a) a nucleic acid sequence as represented by the sequence in FIG. 9, 10, 11, 12, 13 or 14 or fragment thereof;
- b) a nucleic acid sequence which hybridises to the nucleic acid sequences of FIG. 9, 10, 11, 12, 13 or 14 and encodes a gene for PARP;
- c) a nucleic acid sequence which comprise sequences which are degenerate as a result of the genetic code to the nucleic acid sequences defined in (a) and (b).

Recent studies suggest that RNAi molecules ranging from 100-1000 bp derived from coding sequence are effective inhibitors of gene expression. Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

More preferably said RNAi molecule according has a length of between 10 nucleotide bases (nb)-1000 nb. Even more preferably said RNAi molecule has a length of 10 nb; 20 nb; 30 nb; 40 nb; 50 nb; 60 nb; 70 nb; 80 nb; 90 nb; or 100 bp. Even more preferably still said RNAi molecule is 21 nb in length.

Even more preferably still the RNAi molecule comprises the nucleic acid sequence aaa agc cau ggu gga gua uga (PARP-1)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence aag acc aau cuc ucc agu uca ac (PARP-2)

US 8,859,562 B2

5

Even more preferably still the RNAi molecule consists of the nucleic acid sequence aag acc aac auc gag aac aac (PARP-3)

The RNAi molecule may comprise modified nucleotide bases.

Preferred features of each aspect of the invention are as for each of the other aspects *mutatis mutandis*.

The present invention will now be described by way of example only with reference to the accompanying figures, wherein:

FIG. 1 is a graph demonstrating that HR deficient cells are hypersensitive to the toxic effect caused by inhibition of PARP-1. Colony outgrowth of the Chinese hamster cell lines AA8 (wild-type), irs1SF (deficient in HR[4]), CXR3 (irs1SF complemented with XRCC3 [2]), V79 (wild-type), irs1 (deficient in HR[5]) or irs1X2.2 (irs1 complemented with XRCC2 [1]) upon exposure to 3-AB (A), ISQ (B) or NU1025 (C). The means (symbols) and standard deviation (bars) of at least three experiments are shown. Colony outgrowth assay was used;

FIG. 2 is a graph showing cell survival in the presence of PARP inhibitor NU1025 in wt V79 cells, BRCA2 deficient VC-8 cells and VC-8 cells complemented with functional BRCA2 gene (VC-8#13, VC-8+B2). Colony outgrowth assay was used;

FIG. 3 is a histogram showing the percentage of the cells in apoptosis following a 72 hour incubation with NU1025;

FIG. 4. (a) Western blot analysis of protein lysates isolated from MCF-7 (p53^{wt}) or MDA-MB-231 (p53^{mut}) breast cancer cells following 48 hours transfection with siRNA. (b) Colony outgrowth of siRNA-treated MCF-7 cells or (c) MDA-MB-231 cells following exposure to the PARP inhibitor NU1025. The means (symbols) and standard deviation (bars) of at least three experiments are shown.

FIG. 5. BRCA2 deficient cells fail to repair a recombination lesion formed at replication forks by inhibitors of PARP. (a) Visualization of double strand breaks (DSBs) in BRCA2 proficient or deficient cells following a 24-hour treatment with NU1025 (0.1 mM) by pulse-field gel electrophoresis. Hydroxyurea 2 mM was used as a positive control. (b) Visualisation of γ H2Ax foci in untreated V-C8+B2 and V-C8 cells. Number of cells containing γ H2Ax foci (c) or RAD51 foci (d) visualised in V-C8+B2 and V-C8 cells following a 24-hour treatment with NU1025 (10 μ M). The means (symbols) and standard errors (bars) of three to nine experiments are shown. (e) A suggested model for cell death induced in BRCA2 deficient cells.

FIG. 6. PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion, causing death in absence of BRCA2. (a) RT-PCR on RNA isolated from SW480SN.3 cells treated with BRCA2, PARP-1 and PARP-2 siRNA in combinations as shown for 48 hours. (b) Clonogenic survival following 48-hours depletion of BRCA2, PARP-1 and PARP-2. The means (symbols) and standard deviation (bars) of at least three experiments are shown. Two and three stars designate statistical significance in t-test $p < 0.01$ and $p < 0.001$, respectively. (c) Western blot for PARP-1 in SW480SN.3 cells treated with different siRNA.

FIG. 7. (a) Visualisation of PAR polymers in untreated and (b) thymidine treated V79 cells (5 mM for 24 hours). (c) Percentage cells containing >10 sites of PARP activity following treatment with hydroxyurea (0.2 mM) and thymidine (5 mM). At least 300 nuclei were counted for each treatment and experiment. (d) Survival of V-C8+B2 cells following co-treatment with hydroxyurea or (e) thymidine and NU1025 (10 μ M). (f) The activity of PARP was measured by the level of free NAD(P)H¹¹, following treatment with MMS, hydrox-

6

urea (0.5 mM) or thymidine (10 mM). The means (symbol) and standard deviation (error bars) from at least three experiments are depicted.

FIG. 8. (a) Visualisation of PAR polymers in untreated V-C8 and (b) V-C8+B2 cells. (c) Quantification of percentage cells containing >10 sites of PARP activity in untreated V-C8 and V-C8+B2 cells. (d) Level of NAD(P)H measured in untreated V-C8 and V-C8+B2 cells. Three stars designate $p < 0.001$ in t-test. (e) Visualization of RAD51 and sites of PARP activity in V79 cells following a 24-hour thymidine treatment (5 mM). (f) A model for the role of PARP and HR at stalled replication forks.

FIG. 9 is the human cDNA sequence of PARP-1;

FIG. 10 is the human cDNA sequence of PARP-2;

FIG. 11 is the human cDNA sequence of PARP-3;

FIG. 12 is the human gDNA sequence of Tankyrase 1;

FIG. 13 is the human mRNA sequence of Tankyrase 2;

FIG. 14 is the human mRNA sequence of VPARP.

MATERIALS AND METHODS

Cytotoxicity of PARP Inhibitors to HR-Defective Cells: XRCC2, XRCC3 or BRCA2

Cell Culture

The irs1, irs1X2.1 and V79-4 cell lines were a donation from John Thacker [40] and the AA8, irs1SF and CXR3 cell lines were provided by Larry Thompson [41].

The VC-8, VC-8+B2, VC-8#13 were a gift from Malgorzata Zdzienicka [42]. All cell lines in this study were grown in Dulbecco's modified Eagle's Medium (DMEM) with 10% Foetal bovine serum and penicillin (100 U/ml) and streptomycin sulphate (100 μ g/mL) at 37° C. under an atmosphere containing 5% CO₂.

Toxicity Assay—Colony Outgrowth Assay

500 cells suspended in medium were plated onto a Petri dish 4 hours prior to the addition of 3-AB, ISQ or NU1025. ISQ and NU1025 were dissolved in DMSO to a final concentration of 0.2% in treatment medium. 7-12 days later, when colonies could be observed, these colonies were fixed and stained with methylene blue in methanol (4 g/l). Colonies consisting of more than 50 cells were subsequently counted.

Apoptosis Experiments

0.25 \times 10⁶ cells were plated onto Petri dishes and grown for 4 hours before treatment with NU1025. After 72 hours, cells were trypsinized and resuspended with medium containing any floating cells from that sample. The cells were pelleted by centrifugation and resuspended for apoptosis analysis with FITC-conjugated annexin-V and propidium iodine (PI) (ApoTarget, Biosource International) according to manufacturer's protocol. Samples were analysed by flow cytometry (Becton-Dickenson FACSsort, 488 nm laser), and percentage of apoptotic cells was determined by the fraction of live cells (PI-negative) bound with FITC-conjugated annexin-V.

Immunofluorescence

Cells were plated onto coverslips 4 h prior to 24-h treatments as indicated. Following treatments the medium was removed and coverslips rinsed once in PBS at 37° C. and fixed as described elsewhere [2]. The primary antibodies and dilutions used in this study were; rabbit polyclonal anti PAR (Trevigen; 1:500), goat polyclonal anti Rad51 (C-20, Santa Cruz; 1:200) and rabbit polyclonal anti Rad51 (H-92, Santa Cruz; 1:1000). The secondary antibodies were Cy-3-conjugated goat anti-rabbit IgG antibody (Zymed; 1:500), Alexa 555 goat anti-rabbit F(ab')₂ IgG antibody (Molecular Probes; 1:500), Alexa 546 donkey anti-goat IgG antibody (Molecular Probes; 1:500) and Alexa 488 donkey anti-rabbit IgG antibody (Molecular Probes; 1:500). Antibodies were diluted in

US 8,859,562 B2

7

PBS containing 3% bovine serum albumin. DNA was stained with 1 µg/ml To Pro (Molecular Probes). Images were obtained with a Zeiss LSM 510 inverted confocal microscope using planapochromat 63X/NA 1.4 oil immersion objective and excitation wavelengths 488, 546 and 630 nm. Through focus maximum projection images were acquired from optical sections 0.50 µm apart and with a section thickness of 1.0 µm. Images were processed using Adobe PhotoShop (Abacus Inc). At least 300 nuclei were counted on each slide and those containing more than 10 RAD51 foci or sites of PARP activity were classified as positive.

PARP Activity Assays

A water-soluble tetrazolium salt (5 mM WST-8) was used to monitor the amount of NAD(P)H through its reduction to a yellow coloured formazan dye [43]. 5000 cells were plated in at least triplicate into wells of a 96 well plate and cultured in 100 µl normal growth media for 4 h at 37° C. CK8 buffer (Dojindo Molecular Technology, Gaithersburg, USA), containing WST-8, was then added either with or without treatment with DNA damaging agents at concentrations indicated. Reduction of WST-8 in the presence of NAD(P)H was determined by measuring visible absorbance (OD₄₅₀) every 30 min. A medium blank was also prepared containing just media and CK8 buffer. Changes in NAD(P)H levels were calculated by comparing the absorbance of wells containing cells treated with DNA damaging agents and those treated with DMSO alone. Alternately relative levels of NAD(P)H in different cells lines were calculated after 4 h incubation in CK8 buffer.

The ability of NU1025 to inhibit PARP-1 activity was also assayed in permeabilised cells using a modification of the method of Halldorsson et al [44], and described in detail elsewhere [45]. Briefly: 300 µl of NU1025-treated (15 min) permeabilised cells were incubated at 26° C. with oligonucleotide (final conc. 2.5 µg/ml), 75 µM NAD+[³²P] NAD (Amersham Pharmacia, Amersham, UK) in a total volume of 400 µl. The reaction was terminated after 5 min by adding ice cold 10% TCA 10% Na Ppi for 60 min prior to filtering through a Whatman GF/C filter (LabSales, Maidstone, UK), rinsed 6x with 1% TCA 1% NaPpi, left to dry and incorporated radioactivity was measured to determine PARP-1 activity. Data are expressed as pmol NAD incorporated/10⁶ cells by reference to [³²P] NAD standards.

Pulse-Field Gel Electrophoresis

1.5x10⁶ cells were plated onto 100 mm dishes and allowed 4 h for attachment. Exposure to drug was for 18 h after which cells were trypsinised and 10⁶ cells melted into each 1% agarose insert. These inserts were incubated as described elsewhere (8) and separated by pulse-field gel electrophoresis for 24 h (BioRad; 120° angle, 60 to 240 s switch time, 4 V/cm). The gel was subsequently stained with ethidium bromide for analysis.

siRNA Treatment

Pre-designed BRCA2 SMARTpool and scrambled siRNAs were purchased (Dharmacon, Lafayette, Colo.). 10000 cells seeded onto 6 well plates and left over night before transfected with 100 nM siRNA using Oligofectamine Reagent (Invitrogen) according to manufacturers instructions. Cells were then cultured in normal growth media for 48 h prior to trypsinisation and replating for toxicity assays. Suppression of BRCA2 was confirmed by Western blotting (as described previously [46]) of protein extracts treated with siRNA with an antibody against BRCA2 (Oncogene, Nottingham, UK).

EXAMPLES

Homologous Recombination Deficient Cells are Hypersensitive to PARP-1 Inhibition

To investigate the involvement of HR in cellular responses to inhibition of PARP-1, the effects of PARP-1 inhibitors on

8

the survival of HR repair deficient cell lines were studied. It was found that cells deficient in HR (i.e., irs1SF which is defective in XRCC3 or irs1 which is defective in XRCC2 [see Table 1]) were very sensitive to the toxic effect of 3-aminobenzamide (3-AB) and to two more potent inhibitors of PARP-1: 1,5-dihydroxyisoquinoline (ISQ; [37]) or 8-hydroxy-2-methylquinazolinone (NU1025 [38, 39]) (FIG. 1). The sensitivity in irs1SF cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional XRCC3 gene (CXR3). Similarly, the sensitivity in irs1 cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional XRCC2 gene (irs1X2.2).

BRCA2 Deficient Cells are Hypersensitive to PARP-1 Inhibition

The survival of BRCA2 deficient cells (VC8) and wild type cells (V79Z) in the presence of inhibitors of PARP-1 was investigated. It was found that VC8 cells are very sensitive to the toxic effect of NU1025 (FIG. 2). The sensitivity in VC8 cells was corrected by the introduction of a functional BRCA2 gene either on chromosome 13 (VC8#13) or on an overexpression vector (VC8+B2). This result demonstrates that the sensitivity to PARP-1 inhibitors is a direct consequence of loss of the BRCA2 function.

To investigate if inhibition of PARP-1 triggers apoptosis in BRCA2 deficient cells, the level of apoptosis 72 hours following exposure to NU1025 was investigated. It was found that NU1025 triggered apoptosis only in VC8 cells, showing that loss of PARP-1 activity in BRCA2 deficient cells triggers this means of death (FIG. 3).

BRCA2 Deficient Breast Cancer Cells are Hypersensitive to PARP-1 Inhibition

It was examined whether the MCF7 (wild-type p53) and MDA-MB-231 (mutated p53) breast cancer cell lines displayed a similar sensitivity to NU1025 upon depletion of BRCA2. It was found that PARP inhibitors profoundly reduced the survival of MCF7 and MDA-MB-231 cells only when BRCA2 was depleted with a mixture of BRCA2 siRNA (FIG. 4). This shows that BRCA2 depleted breast cancer cells are sensitive to PARP inhibitors regardless of p53 status.

BRCA2 Deficient Cells Die from PARP-1 Inhibition in Absence of DNA Double-Strand Breaks (DSBs) but in Presence of γH2Ax

HR is known to be involved in the repair of DSBs and other lesions that occur during DNA replication [2]. To determine whether the sensitivity of BRCA2 deficient cells is the result of an inability to repair DSBs following NU1025 treatment, the accumulation of DSBs in V79 and V-C8 cells was measured following treatments with highly toxic levels of NU1025. It was found that no DSBs were detectable by pulsed field gel electrophoretic analysis of DNA obtained from the treated cells (FIG. 5A), suggesting that low levels of DSBs or other recombinogenic substrates accumulated following PARP inhibition in HR deficient cells, which trigger γH2Ax (FIG. 5B). The reason why BRCA2 deficient cells die following induction of these recombinogenic lesions is likely to be due to an inability to repair such lesions. To test this, the ability of BRCA2 deficient V-C8 cells and BRCA2 complemented cells to form RAD51 foci in response to NU1025 was determined. It was found that RAD51 foci were indeed induced in V-C8+B2 cells following treatment with NU1025 (statistically significant in t-test p<0.05; FIG. 5D). This indicates that the recombinogenic lesions trigger HR repair in these cells allowing them to survive. In contrast, the BRCA2 deficient V-C8 cells were unable to form RAD51 foci in response to NU1025 treatment (FIG. 5D) indicating no HR, which would leave the recombinogenic lesions unrepaired and thus cause cell death.

PARP-1 and Not PARP-2 is Important in Preventing Formation of a Recombinogenic Lesion

There are two major PARPs present in the nucleus in mammalian cells, PARP-1 and PARP-2 and all reported PARP inhibitors inhibit both. In order to distinguish which PARP was responsible for the effect, we tested if the absence of PARP-1 and/or PARP-2 results in accumulation of toxic lesions, by depleting these and BRCA2 with siRNA in human cells (FIG. 6a). We found that the clonogenic survival was significantly reduced when both PARP-1 and BRCA2 proteins were co-depleted from human cells (FIG. 6b). Depletion of PARP-2 with BRCA2 had no effect on the clonogenic survival and depletion of PARP-2 in PARP-1 and BRCA2 depleted cells did not result in additional toxicity. These results suggest that PARP-1 and not PARP-2 is responsible for reducing toxic recombinogenic lesions in human cells. The cloning efficiency was only reduced to 60% of control in PARP-1 and BRCA2 co-depleted cells, while no HR deficient cells survived treatments with PARP inhibitors. This is likely to do with incomplete depletion of the abundant PARP-1 protein by siRNA (FIG. 6c), which might be sufficient to maintain PARP-1 function in some of the cells.

PARP-1 is Activated by Replication Inhibitors

HR is also involved in repair of lesions occurring at stalled replication forks, which may not involve detectable DSBs [2]. To test if PARP has a role at replication forks, PARP activation in cells treated cells with agents (thymidine or hydroxyurea) that retard or arrest the progression of DNA replication forks was examined. Thymidine depletes cells of dCTP and slows replication forks without causing DSBs. Hydroxyurea depletes several dNTP and block the replication fork, which is associated with the formation of DSBs at replication forks [2]. Both of these agents potentially induce HR [2]. V79 hamster cells treated for 24 hours with thymidine or hydroxyurea were stained for PAR polymers. This revealed a substantial increase in the number of cells containing sites of PARP activity (FIG. 7C). This result suggests a function for PARP at stalled replication forks. It was also shown that inhibition of PARP with NU1025 enhances the sensitivity to thymidine or hydroxyurea in V-C8+B2 cells (FIG. 7D,E). This result suggests that PARP activity is important in repair of stalled replication forks or alternatively that it prevents the induction of death in cells with stalled replication forks.

PARP is rapidly activated at DNA single-strand breaks (SSB) and attracts DNA repair enzymes [3-6]. Methylmethane sulphonate (MMS) causes alkylation of DNA, which is repaired by base excision repair. PARP is rapidly activated by the SSB-intermediate formed during this repair, which depletes the NAD(P)H levels (FIG. 7F). We found that the activation of PARP and reduction of NAD(P)H levels is much slower following thymidine or hydroxyurea treatments. This slow PARP activation can be explained by the indirect action of thymidine and hydroxyurea and the time required to accumulate stalled replication forks as cells enter the S phase of the cell cycle.

PARP-1 and HR Have Separate Roles at Stalled Replication Forks

The number sites of PARP activity in untreated BRCA2 deficient V-C8 cells was determined. It was found that more V-C8 cells contain sites of PARP activity compared to V-C8+B2 cells (FIG. 8A,B,C). Also, the V-C8 cells have lower free NAD(P)H levels than the corrected cells (FIG. 8D), as a likely result of the increased PARP activity. Importantly these sites of PARP activity do not overlap with RAD51 foci (FIG. 8E).

The results herein suggest that PARP and HR have separate roles in the protection or rescue of stalled replication forks (FIG. 8F). A loss of PARP activity can be compensated by

increased HR while a loss of HR can be compensated by increased PARP activity. However, loss of both these pathways leads to accumulation of stalled replication forks and to death, as in the case of PARP inhibited BRCA2 deficient cells.

As shown in the model outlined in FIG. 8F PARP and HR have complementary roles at stalled replication forks. (i) Replication forks may stall when encountering a roadblock on the DNA template. In addition, they may also stall temporarily, due to lack of dNTPs or other replication co-factors. (ii) PARP binds stalled replication forks or other replication-associated damage, triggering PAR polymerization. Resulting negatively charged PAR polymers may protect stalled replication forks, by repelling proteins that normally would process replication forks (e.g., resolvases), until the replication fork can be restored spontaneously when dNTPs or other co-factors become available. Alternatively, PAR polymers or PARP may attract proteins to resolve the replication block by other means. (iii) In absence of PARP activity, HR may be used as an alternative pathway to repair stalled replication forks. This compensatory model explains the increased level of HR and RAD51 foci found in PARP deficient cells³⁻⁵ and higher PARP activity found in HR deficient cells (i.e. V-C8). Spontaneous replication blocks/lesions are only lethal in the absence of both PARP and HR.

TABLE 1

| Genotype and origin of cell lines used in this study. | | | | |
|---|-----------------------------|--------------------------------------|--------|-----------|
| Cell line | Genotype | Defect | Origin | Reference |
| AA8 | Wt | Wt | CHO | [41] |
| irs1SF | XRCC3 ⁻ | XRCC3 ⁻ , deficient in HR | AA8 | [41] |
| CXR3 | XRCC3 ⁻ + hXRCC3 | Wt | irs1SF | [41] |
| V79-4 | Wt | Wt | V79 | [40] |
| irs1 | XRCC2 ⁻ | XRCC2 ⁻ , deficient in HR | V79-4 | [40] |
| irs1X2.2 | XRCC2 ⁻ + hXRCC2 | Wt | irs1 | [40] |
| V79-Z | Wt | Wt | V79 | [42] |
| VC8 | BRCA2 ⁻ | BRCA2 ⁻ , deficient in HR | V79-Z | [42] |
| VC8#13 | BRCA2 ⁻ + hBRCA2 | Wt | VC8 | [42] |
| VC8 + B2 | BRCA2 ⁻ + hBRCA2 | Wt | VC8 | [42] |

REFERENCES

- [1] A. R. Venkitaraman Cancer susceptibility and the functions of BRCA1 and BRCA2, *Cell* 108 (2002) 171-182.
- [2] C. Lundin, K. Erixon, C. Arnaudeau, N. Schultz, D. Jensen, M. Meuth and T. Helleday Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells, *Mol Cell Biol* 22 (2002) 5869-5878.
- [3] D. D'Amours, S. Desnoyers, I. D'Silva and G. G. Poirier Poly(ADP-ribosylation) reactions in the regulation of nuclear functions, *Biochem J* 342 (1999) 249-268.
- [4] Z. Herceg and Z. Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death, *Mutat Res* 477 (2001) 97-110.
- [5] T. Lindahl, M. S. Satoh, G. G. Poirier and A. Klungland Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks, *Trends Biochem Sci* 20 (1995) 405-411.
- [6] M. S. Satoh and T. Lindahl Role of poly(ADP-ribose) formation in DNA repair, *Nature* 356 (1992) 356-358.

US 8,859,562 B2

11

[7] S. Shall and G. de Murcia Poly(ADP-ribose)polymerase-1: what have we learned from the deficient mouse model?, *Mutat Res* 460 (2000) 1-15.

[8] Z. Q. Wang, L. Stingl, C. Morrison, M. Jantsch, M. Los, K. Schulze-Osthoff and E. F. Wagner PARP is important for genomic stability but dispensable in apoptosis, *Genes Dev* 11 (1997) 2347-2358.

[9] C. M. Simbulan-Rosenthal, B. R. Haddad, D. S. Rosenthal, Z. Weaver, A. Coleman, R. Luo, H. M. Young, Z. Q. Wang, T. Ried and M. E. Smulson Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA, *Proc Natl Acad Sci USA* 96 (1999) 13191-13196.

[10] J. M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F. J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walzinger, P. Chambon and G. de Murcia Requirement of poly(ADP-ribose)polymerase in recovery from DNA damage in mice and in cells, *Proc Natl Acad Sci USA* 94 (1997) 7303-7307.

[11] F. d'Adda di Fagagna, M. P. Hande, W. M. Tong, P. M. Lansdorp, Z. Q. Wang and S. P. Jackson Functions of poly(ADP-ribose)polymerase in controlling telomere length and chromosomal stability, *Nat Genet* 23 (1999) 76-80.

[12] E. Samper, F. A. Goytisolo, J. Menissier-de Murcia, E. Gonzalez-Suarez, J. C. Cigudosa, G. de Murcia and M. A. Blasco Normal telomere length and chromosomal end capping in poly(ADP-ribose)polymerase-deficient mice and primary cells despite increased chromosomal instability, *J Cell Biol* 154 (2001) 49-60.

[13] C. Morrison, G. C. Smith, L. Stingl, S. P. Jackson, E. F. Wagner and Z. Q. Wang Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis, *Nat Genet* 17 (1997) 479-482.

[14] V. Schreiber, D. Hunting, C. Trucco, B. Gowans, D. Grunwald, G. De Murcia and J. M. De Murcia A dominant-negative mutant of human poly(ADP-ribose)polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage, *Proc Natl Acad Sci USA* 92 (1995) 4753-4757.

[15] J. H. Kupper, M. Muller and A. Burkle Trans-dominant inhibition of poly(ADP-ribosylation) potentiates carcinogen induced gene amplification in SV40-transformed Chinese hamster cells, *Cancer Res* 56 (1996) 2715-2717.

[16] J. Magnusson and C. Ramel Inhibitor of poly(ADP-ribose)transferase potentiates the recombinogenic but not the mutagenic action of alkylating agents in somatic cells in vivo in *Drosophila melanogaster*, *Mutagenesis* 5 (1990) 511-514.

[17] A. S. Waldman and B. C. Waldman Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation), *Nucleic Acids Res* 19 (1991) 5943-5947.

[18] A. Semionov, D. Cournoyer and T. Y. Chow Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts, *Nucleic Acids Res* 27 (1999) 4526-4531.

[19] F. Dantzer, V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, J. Oliver, V. Rolli, J. Menissier-de Murcia and G. de Murcia Involvement of poly(ADP-ribose)polymerase in base excision repair, *Biochimie* 81 (1999) 69-75.

[20] F. Dantzer, G. de La Rubia, J. Menissier-De Murcia, Z. Hostomsky, G. de Murcia and V. Schreiber Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose)polymerase-1, *Biochemistry* 39 (2000) 7559-7569.

12

[21] L. Tentori, I. Portarena and G. Graziani Potential clinical applications of poly(ADP-ribose)polymerase (PARP) inhibitors, *Pharmacol Res* 45 (2002) 73-85.

[22] T. Lindahl and R. D. Wood Quality control by DNA repair, *Science* 286 (1999) 1897-1905.

[23] K. W. Caldecott DNA single-strand break repair and spinocerebellar ataxia, *Cell* 112 (2003) 7-10.

[24] D. D'Amours and S. P. Jackson The Mre11 complex: at the crossroads of dna repair and checkpoint signalling, *Nat Rev Mol Cell Biol* 3 (2002) 317-327.

[25] A. D. D'Andrea and M. Grompe The Fanconi anaemia/BRCA pathway, *Nat Rev Cancer* 3 (2003) 23-34.

[26] S. P. Jackson Sensing and repairing DNA double-strand breaks, *Carcinogenesis* 23 (2002) 687-696.

[27] R. Kanaar, J. H. Hoeijmakers and D. C. van Gent Molecular mechanisms of DNA double strand break repair, *Trends Cell Biol* 8 (1998) 483-489.

[28] D. C. van Gent, J. H. Hoeijmakers and R. Kanaar Chromosomal stability and the DNA double-stranded break connection, *Nat Rev Genet* 2 (2001) 196-206.

[29] S. L. Neuhausen and E. A. Ostrander Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2, *Genet Test* 1 (1997) 75-83.

[30] G. Kuperstein, W. D. Foulkes, P. Ghadirian, J. Hakimi and S. A. Narod A rapid fluorescent multiplexed-PCR analysis (FMFA) for founder mutations in the BRCA1 and BRCA2 genes, *Clin Genet* 57 (2000) 213-220.

[31] A. Chiarugi Poly(ADP-ribose)polymerase: killer or conspirator? The 'suicide hypothesis' revisited, *Trends Pharmacol Sci* 23 (2002) 122-129.

[32] C. R. Calabrese, M. A. Batey, H. D. Thomas, B. W. Durkacz, L. Z. Wang, S. Kyle, D. Skaltitzky, J. Li, C. Zhang, T. Boritzki, K. Maegley, A. H. Calvert, Z. Hostomsky, D. R. Newell and N. J. Curtin Identification of Potent Nontoxic Poly(ADP-Ribose)Polymerase-1 inhibitors: Chemopotentiation and Pharmacological Studies, *Clin Cancer Res* 9 (2003) 2711-2718.

[33] D. Ferraris, Y. S. Ko, T. Pahutski, R. P. Ficco, L. Serdyuk, C. Alemu, C. Bradford, T. Chiou, R. Hoover, S. Huang, S. Lautar, S. Liang, Q. Lin, M. X. Lu, M. Mooney, L. Morgan, Y. Qian, S. Tran, L. P. Williams, Q. Y. Wu, J. Zhang, Y. Zou and V. Kalish Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5 [H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries, *J Med Chem* 46 (2003) 3138-3151.

[34] K. J. Dillon, G. C. Smith and N. M. Martin A FlashPlate assay for the identification of PARP-1 inhibitors, *J Biomol Screen* 8 (2003) 347-352.

[35] A. J. Pierce, R. D. Johnson, L. H. Thompson and M. Jasin XRCC3 promotes homology-directed repair of DNA damage in mammalian cells, *Genes Dev* 13 (1999) 2633-2638.

[36] R. D. Johnson, N. Liu and M. Jasin Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination, *Nature* 401 (1999) 397-399.

[37] G. M. Shah, D. Poirier, S. Desnoyers, S. Saint-Martin, J. C. Hoflack, P. Rong, M. ApSimon, J. B. Kirkland and G. G. Poirier Complete inhibition of poly(ADP-ribose)polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress, *Biochim Biophys Acta* 1312 (1996) 1-7.

[38] R. J. Griffin, S. Srinivasan, K. Bowman, A. H. Calvert, N. J. Curtin, D. R. Newell, L. C. Pemberton and B. T. Golding Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP), *J Med Chem* 41 (1998) 5247-5256.

US 8,859,562 B2

13

- [39] S. Boulton, L. C. Pemberton, J. K. Porteous, N. J. Curtin, R. J. Griffin, B. T. Golding and B. W. Durkacz Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose)polymerase inhibitors, *Br J Cancer* 72 (1995) 849-856.
- [40] C. S. Griffin, P. J. Simpson, C. R. Wilson and J. Thacker Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation, *Nat Cell Biol* 2 (2000) 757-761.
- [41] R. S. Tebbs, Y. Zhao, J. D. Tucker, J. B. Scheerer, M. J. Siciliano, M. Hwang, N. Liu, R. J. Legerski and L. H. Thompson Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene, *Proc Natl Acad Sci USA* 92 (1995) 6354-6358.
- [42] M. Kraakman-van der Zwet, W. J. Overkamp, R. E. van Lange, J. Essers, A. van Duijn-Goedhart, I. Wiggers, S. Swaminathan, P. P. van Buul, A. Errami, R. T. Tan, N. G. Jaspers, S. K. Sharan, R. Kanaar and M. Z. Zdzienicka *Brca2* (XRCC11) deficiency results in radioresistant DNA

14

- synthesis and a higher frequency of spontaneous deletions, *Mol Cell Biol* 22 (2002) 669-679.
- [43] J. Nakamura, S. Asakura, S. D. Hester, G. de Murcia, K. W. Caldecott and J. A. Swenberg Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time, *Nucleic Acids Res* 31 (2003) e104.
- [44] H. Halldorsson, D. A. Gray and S. Shall Poly(ADP-ribose)polymerase activity in nucleotide permeable cells, *FEBS Lett* 85 (1978) 349-352.
- [45] K. Grube, J. H. Kupper and A. Burkle Direct stimulation of poly(ADP ribose)polymerase in permeabilized cells by double-stranded DNA oligomers, *Anal Biochem* 193 (1991) 236-239.
- [46] C. Lundin, N. Schultz, C. Amaudeau, A. Mohindra, L. T. Hansen and T. Helleday RAD51 is Involved in Repair of Damage Associated with DNA Replication in Mammalian Cells, *J Mol Biol* 328 (2003) 521-535.
- [47] Schreider et al., *Journal of Biological Chemistry* 277: 23028-23036 (2002).

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 9

<210> SEQ ID NO 1

<211> LENGTH: 21

<212> TYPE: RNA

<213> ORGANISM: *Homo sapiens*

<400> SEQUENCE: 1

aaaagccaug guggaguaug a

21

<210> SEQ ID NO 2

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: *Homo sapiens*

<400> SEQUENCE: 2

aagaccaauc ucuccaguuc aac

23

<210> SEQ ID NO 3

<211> LENGTH: 21

<212> TYPE: RNA

<213> ORGANISM: *Homo sapiens*

<400> SEQUENCE: 3

aagaccaaca ucgagaacaa c

21

<210> SEQ ID NO 4

<211> LENGTH: 5468

<212> TYPE: DNA

<213> ORGANISM: *Homo sapiens*

<400> SEQUENCE: 4

cgcccgccca gccccggggg cagggaaagc ctaaattacg gaattaccgc gagcaaggag 60

cgcggaatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tgatgggaat 120

ctttgcaaat tgtatcttct gtttgaaagt gaagtactta cctcagcagc agaagaaaaa 180

gctacaaact gacattaagg aaaatggcgg aaagttttcc ttttcgttaa atcctcagtg 240

cacacatata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca 300

aaagaaccac gttcatattg caaaccaga ttttatatgg aaatctatca gagaaaagag 360

actcttgat gtaaagaatt atgacctta taagccctg gacatcacac cacctcctga 420

US 8,859,562 B2

15

16

-continued

| | |
|---|------|
| tcagaaggcg agcagttctg aagtgtaaaac agaaggtcta tgcccggaaca gtgccacaga | 480 |
| ggaggaagac actgtggaac tcaactgagtt tggtagtcag aatgttgaaa ttctcatct | 540 |
| tcctcaagat ttgaagttg caaaatataa caccttgag aaagtggga tggaggagg | 600 |
| ccaggaagct gtggtggtg agcttcagtg ttcgctggac tccagggact gtcctttcct | 660 |
| gatatcctca cacttcctcc tggatgatgg catggagact agaagacagt ttgctataaa | 720 |
| gaaaacctct gaagatgcaa gtgaatactt tgaaaattac attgaagaac tgaagaaca | 780 |
| aggatttcta ctaagagaac atttcacacc tgaagcaacc caattagcat ctgaacaatt | 840 |
| gcaagcattg cttttggagg aagtcatgaa ttcaagcact ctgagccaag aggtgagcga | 900 |
| tttagtagag atgatttggg cagaggccct gggccacctg gaacacatgc ttctcaagcc | 960 |
| agtgaacagg attagcctca acgatgtgag caaggcagag gggattctcc ttctagtaaa | 1020 |
| ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagtttta | 1080 |
| cagactgata cctcacaaa gcacaatgcc caaagaagtg aacctgggac tattggctaa | 1140 |
| gaaagcagac ctctgccagc taataagaga catggttaat gtctgtgaaa ctaatttgtc | 1200 |
| caaacccaac ccaccatccc tggccaaata ccgagctttg aggtgcaaaa ttgagcatgt | 1260 |
| tgaacagaat actgaagaat ttctcagggt tagaaaagag gttttgcaga atcatcacag | 1320 |
| taagagccca gtggatgtct tgcagatatt tagagttggc agagtgaatg aaaccacaga | 1380 |
| gtttttgagc aaacttggtg atgtgagggc cttgttgcat ggttctcctg taaaaacat | 1440 |
| cgtgggaatc ttgtgtcgag ggttgctttt acccaaagta gtggaagatc gtggtgtgca | 1500 |
| aagaacagac gtcggaacc ttggaagtgg gatttatctc agtgattcgc tcagtacaag | 1560 |
| tatcaagtac tcacaccgg gagagacaga tggcaccaga ctctgtctca ttgtgacgt | 1620 |
| agccctcgga aagtgtatgg acttacatga gaaggacttt tccttaactg aagcaccacc | 1680 |
| aggctacgac agtgtgcatg gagtttcaca aacagcctct gtcaccacag actttgagga | 1740 |
| tgatgaattt gttgtctata aaaccaatca gggttaaatg aaatatatta ttaaattttc | 1800 |
| catgctgga gatcagataa aggactttca tcttagtgat catactgaat tagaggata | 1860 |
| cagacctgag ttttcaaatt tttcaaagg tgaagattac cagttaccag atgcaaaaac | 1920 |
| ttccagcagc accaaggccg gcctccagga tgcttctggg aacttggttc ctctggagga | 1980 |
| tgccacatc aaagggagaa tcatagacac ttagagccag gtcattgttt ttccagacata | 2040 |
| cacaaataaa agtcacgtgc ccattgagggc aaaatatatc tttcctttgg atgacaaggc | 2100 |
| cgctgtgtgt ggtctcgaag ccttcacaa tgggaagcac atagttggag agattaaaga | 2160 |
| gaaggagaa gcccgcaag agtacctaga agccgtgacc cagggccatg gcgcttacct | 2220 |
| gatgagtcag gatgctccgg acgtttttac tgtaagtgtt ggaaacttac ccctaaaggc | 2280 |
| taaggttctt ataaaaatta cctacatcac agaactcagc atcctgggca ctgttggtgt | 2340 |
| ctttttcatg cccgccaccg tagcaccctg gcaacaggac aaggctttga atgaaaacct | 2400 |
| tcaggataca gtagagaaga ttgtataaa agaaatagga acaagcaaa gcttctcttt | 2460 |
| gactatgtct attgagatgc cgtacgtgat tgaattcatt ttcaagtata ctcatgaact | 2520 |
| gaaacaaaag cgcacagact gcaaagctgt cattagcacc atggaaggca gctccttaga | 2580 |
| cagcagtgga ttttctctcc acatcggttt gtctgctgcc tatctcccaa gaatgtgggt | 2640 |
| tgaaaaacat ccagaaaaag aaagcgaggc ttgcatgctt gtctttcaac ccgatctcga | 2700 |
| tgctgacctc cctgacctag ccaatgagag cgaagtgatt atttgtcttg actgctccag | 2760 |

US 8,859,562 B2

17

18

-continued

| | |
|--|------|
| ttccatggag ggtgtgacat tcttgcaagc caaggaaatc gccttgcatg cgtgtgcctt | 2820 |
| ggtgggtgag aagcagaaaag taaatattat ccagttcggc acaggttaca aggagctatt | 2880 |
| ttcgtatcct aagcatatca caagcaatac cgcggcagca gagttcatca tgtctgccac | 2940 |
| acctaccatg gggaacacag acttctggaa aacactccga tatcttagct tattgtaccc | 3000 |
| tgctcgaggg tcacggaaca tcctcctggt gtctgatggg cacctccagg atgagagcct | 3060 |
| gacattacag ctctgtgaaga ggagcggccc gcacaccagg ttattcgctt gcggtatcgg | 3120 |
| ttctacagca aatcgtcacg tcttaaggat tttgtcccag tgtggtgccg gagtatttga | 3180 |
| atattttaat gcaaaatcca agcatagttg gagaaaacag atagaagacc aaatgaccag | 3240 |
| gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc | 3300 |
| gcccagggcc ctgcaggccc cagcccagggt gccatccttg tttcgcaatg atcgactcct | 3360 |
| tgtctatgga ttcatctctc actgcacaca ggcaactctg tgtgcactaa ttcaagagaa | 3420 |
| agaattttgt acaatgggtg cgactactga gcttcagaag acaactggaa ctatgatcca | 3480 |
| caagctggca gcccagagctc taatcagaga ttatgaagat ggcatctctc acgaaaatga | 3540 |
| aaccagtcac gagatgaaaa aacaaacctt gaaatctctg attattaaac tcagtaaaga | 3600 |
| aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaagg atgagaatga | 3660 |
| gtcacctttt cctgatattc caaaagtctc tgaacttatt gccaaagaag atgtagactt | 3720 |
| cctgccttac atgagctggc aggggggaacc ccaagaagcc gtcaggaacc agtctctttt | 3780 |
| agcatcctct gagtggccag aattacgttt atccaaacga aaacatagga aaattccatt | 3840 |
| ttccaaaaga aaaatggaat tatctcagcc agaagtttct gaagattttg aagaggatgc | 3900 |
| cttaggtgta ctaccagctt tcacatcaaa tttggaacgt ggacgtgtgg aaaagctatt | 3960 |
| ggatttaagt tggacagagt catgtaaacc aacagcaact gaaccactat ttaagaaagt | 4020 |
| cagtccatgg gaaacatcta cttctagctt ttttctatt ttggctccgg ccgttggttc | 4080 |
| ctatcttacc ccgactaccc gcgctcacag tcctgcttcc ttgtcttttg cctcatatcg | 4140 |
| tcaggtagct agtttcggtt cagctgctcc tcccagacag tttgatgcac ctcaattcag | 4200 |
| ccaagccct gtgcctggca cttgtgctga ctggatcca cagtcggcgt cttgtccac | 4260 |
| aggacctccc cagaaccac cttctgcacc ctattgtggc attgtttttt cagggagctc | 4320 |
| attaagctct gcacagtctg ctccactgca acatcctgga ggctttacta ccaggccttc | 4380 |
| tgctggcacc ttccctgagc tggattctcc ccagcttcat ttctctcttc ctacagacc | 4440 |
| tgatccatc agaggttttg ggtcttatca tcctctgct tactctcctt ttcattttca | 4500 |
| accttcgcga gcctctttga ctgccaacct taggctgcca atggcctctg ctttacctga | 4560 |
| ggctctttgc agtcagtcct ggactacccc agtagatctc tgtcttctag aagaatcagt | 4620 |
| aggcagctct gaaggaagtc gatgtcctgt ctttgctttt caaagtctg acacagaaag | 4680 |
| tgatgagcta tcagaagtac ttcaagacag ctgcttttta caaataaaat gtgatacaaa | 4740 |
| agatgacagt atcccgtgct ttctggaagt aaaagaagag gatgaaatag tgtgcacaca | 4800 |
| acactggcag gatgctgtgc cttggacaga actcctcagt ctacagacag aggatggctt | 4860 |
| ctggaaactt acaccagaac tgggacttat attaaatctt aatacaaatg gtttgacag | 4920 |
| ctttcttaaa caaaaaggca ttcaatctct aggtgtaaaa ggaagagaat gtctcctgga | 4980 |
| cctaattgcc acaatgctgg tactacagtt tattcgacc aggttggaag aagagggaat | 5040 |
| agtggtcaaa tcaactgatga aaatggatga ccttctatt tccaggaata ttccctgggc | 5100 |
| ttttgaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc | 5160 |

US 8,859,562 B2

19

20

-continued

| | | | | | | |
|------------|------------|------------|------------|------------|------------|------|
| tatctgcccc | cggttgaac | tggggaacga | ctgggactct | gccaccaagc | agttgctggg | 5220 |
| actccagccc | ataagcactg | tgtccccctc | tcatagagtc | ctccattaca | gtcaaggcta | 5280 |
| agtcaaatga | aactgaattt | taaacttttt | gcatgcttct | atgtagaaaa | taatcaaatg | 5340 |
| ataatagata | cttataatga | aacttcatta | aggtttcatt | cagtgtagca | attactgtct | 5400 |
| ttaaaaatta | agtgaagaa | gaattacttt | aatcaactaa | caagcaataa | taaaatgaaa | 5460 |
| cttaaaat | | | | | | 5468 |

<210> SEQ ID NO 5
 <211> LENGTH: 1910
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

| | | | | | | |
|-------------|-------------|-------------|------------|------------|------------|------|
| ctagaattca | gcgcccgctg | aattctaggc | ggcgccggcg | cgacggagca | ccggccggcg | 60 |
| caggggcaga | gcattaaatg | aaagcaaaag | agttaataat | ggcaacacgg | ctccagaaga | 120 |
| ctcttcccc | gccaaagaaa | ctcgtagatg | ccagagacag | gagtcgaaaa | agatgcctgt | 180 |
| ggctggagga | aaagctaata | aggacaggac | agaagacaag | caagatggta | tgccaggaag | 240 |
| gtcatgggcc | agcaaaagg | tctctgaatc | tgtgaaggcc | ttgctgttaa | agggcaaagc | 300 |
| tctgtggac | ccagagtgtg | cagccaaggt | ggggaaggct | catgtgtatt | gtgaaggaaa | 360 |
| tgatgtctat | gatgtcatgc | taaatcagac | caatctccag | ttcaacaaca | acaagtacta | 420 |
| tctgattcag | ctattagaag | atgatgccca | gaggaacttc | agtgtttgga | tgagatgggg | 480 |
| ccgagttggg | aaaatgggac | agcacagcct | ggtggcttgt | tcaggcaatc | tcaacaaggc | 540 |
| caaggaaatc | tttcagaaga | aattccttga | caaaacgaaa | aacaattggg | aagatcgaga | 600 |
| aaagtttgag | aagggtgcctg | gaaaatatga | tatgctacag | atggactatg | ccaccaatac | 660 |
| tcaggatgaa | gaggaacaaa | aaaaagagga | atctcttaaa | tctcccttga | agccagagtc | 720 |
| acagctagat | cttcgggtac | aggagttaat | aaagttgatc | tgtaatgttc | aggccatgga | 780 |
| agaaatgatg | atggaaatga | agtataatac | caagaaagcc | ccacttggga | agctgacagt | 840 |
| ggcacaatc | aaggcagggt | accagtctct | taagaagatt | gaggattgta | ttcgggctgg | 900 |
| ccagcatgga | cgagctctca | tggaaagcatg | caatgaattc | tacaccagga | ttccgcatga | 960 |
| ctttggactc | cgtactcctc | cactaatccg | gacacagaag | gaactgtcag | aaaaaataca | 1020 |
| attactagag | gctttgggag | acattgaaat | tgctattaag | ctggtgaaaa | cagagctaca | 1080 |
| aagcccagaa | cacccattgg | accaacacta | tagaaaccta | cattgtgcct | tgcgccccct | 1140 |
| tgaccatgaa | agttacagag | tcaaagtgat | ttcccagtac | ctacaatcta | cccatgctcc | 1200 |
| cacacacagc | gactatacca | tgaccttgct | ggatttggtt | gaagtggaga | aggatgggtg | 1260 |
| gaaagaagcc | ttcagagagg | accttcataa | caggatgctt | ctatggcatg | gttcagggat | 1320 |
| gagtaactgg | gtgggaatct | tgagccatgg | gcttcgaatt | gccccacctg | aagctcccat | 1380 |
| cacagggttac | atgtttggga | aaggaaatcta | ctttgctgac | atgtcttcca | agagtgccaa | 1440 |
| ttactgcttt | gcctctcgcc | taaagaatac | aggactgctg | ctcttatcag | aggtagctct | 1500 |
| aggtcagtgt | aatgaactac | tagaggccaa | tcctaaggcc | gaaggattgc | ttcaaggtaa | 1560 |
| acatagcacc | aaggggctgg | gcaagatggc | tcccagttct | gcccacttcg | tcaccctgaa | 1620 |
| tgggagtaca | gtgccattag | gaccagcaag | tgacacagga | attctgaatc | cagatgggta | 1680 |
| tacctcaac | tacaatgaat | atattgtata | taacccaac | caggtccgta | tgcggtacct | 1740 |

US 8,859,562 B2

21

22

-continued

| | |
|--|------|
| ttaaaggtt cagtttaatt tccttcagct gtggtgaatg ttgatcttaa ataaaccaga | 1800 |
| gatctgatct tcaagcaaga aaataagcag tgtgtactt gtgaattttg tgatatttta | 1860 |
| tgtaataaaa actgtacagg tctaaaaaaa aaaaaaaaaa aaaaaaaaaa | 1910 |

<210> SEQ ID NO 6
 <211> LENGTH: 2263
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

| | |
|--|------|
| tgggactggt cgctgactc ggcctgcccc agcctctgct tcacccact ggtggccaaa | 60 |
| tagccgatgt ctaatcccc acacaagctc atccccggcc tctgggattg ttgggaattc | 120 |
| tctccctaatt tcacgcctga ggctcatgga gagttgctag acctgggact gccctgggag | 180 |
| gcgcacacaa ccaggccggg tggcagccag gacctctccc atgtccctgc ttttcttggc | 240 |
| catggctcca aagccgaagc cctgggtaca gactgagggc cctgagaaga agaagggccg | 300 |
| gcaggcagga agggaggagg accccttccg ctccaccgct gaggccctca aggccatacc | 360 |
| cgcagagaag cgcataatcc gcgtggatcc aacatgtcca ctccagcagca accccgggac | 420 |
| ccaggtgtat gaggactaca actgcaccct gaaccagacc aacatcgaga acaacaacaa | 480 |
| caagttctac atcatccagc tgctccaaga cagcaaccgc ttcttcacct gctggaaccg | 540 |
| ctggggccgt gtgggagagg tcggccagtc aaagatcaac cacttcacaa ggctagaaga | 600 |
| tgcaaagaag gactttgaga agaaatttcg ggaaaagacc aagaacaact gggcagagcg | 660 |
| ggaccacttt gtgtctcacc cgggcaagta cacacttatc gaagtacagg cagaggatga | 720 |
| ggcccaggaa gctgtggtga aggtggacag agggccagtg aggactgtga ctaagcgggt | 780 |
| gcagccctgc tccctggacc cagccacgca gaagctcatc actaacatct tcagcaagga | 840 |
| gatgttcaag aacaccatgg ccctcatgga cctggatgtg aagaagatgc ccctgggaaa | 900 |
| gctgagcaag caacagattg cacgggggtt cgaggccctg gaggcgctgg aggaggccct | 960 |
| gaaaggcccc acggatgggt gccaaagcct ggaggagctg tcctcacact ttacaccgt | 1020 |
| catcccgcac aacttcggcc acagccagcc cccgcccatc aattcccctg agcttctgca | 1080 |
| ggccaagaag gacatgctgc tgggtgctggc ggacatcgag ctggcccagg cctgcaggc | 1140 |
| agtctctgag caggagaaga cgggtggagga ggtgccacac cccctggacc gagactacca | 1200 |
| gcttctcaag tgccagctgc agctgctaga ctctggagca cctgagtaca agtgatata | 1260 |
| gacctactta gaacagactg gcagcaacca caggtgccct acatttcaac acatctggaa | 1320 |
| agtaaaccaa gaaggggagg aagacagatt ccaggccac tccaaactgg gtaatcgga | 1380 |
| gctgctgtgg catggcacca acatggccgt ggtggccgcc atcctcacta gtgggctccg | 1440 |
| catcatgcca cattctggtg ggcgtgttgg caagggcac tactttgcct cagagaacag | 1500 |
| caagtcagct ggatatgtta ttggcatgaa gtgtggggcc caccatgtcg gctacatgtt | 1560 |
| cctgggtgag gtggccctgg gcagagagca ccatatcaac acggacaacc ccagcttgaa | 1620 |
| gagcccacct cctggcttcg acagtgtcat tgcccaggc cacaccgagc ctgatccgac | 1680 |
| ccaggacact gaggttggagc tggatggcca gcaagtgggt gtgcccagg gccagcctgt | 1740 |
| gccctgcccc gaggttcagca gctccacatt ctcccagagc gagtacctca tctaccagga | 1800 |
| gagccagtggt cgctcgctg acctgctgga ggtccacetc tgagtggccg cctgtcccc | 1860 |
| cggggctcctg caaggtctga ctgtgatctt caatcactct gccatctct ggtaccctta | 1920 |
| tatcactcct ttttttcaag aatacaatac gttgtgttta actatagtca ccatgctgta | 1980 |

US 8,859,562 B2

23

24

-continued

```

caagatccct gaacttatgc ctcttaactg aaatttttga ttctttgaca catctgceca 2040
gtccctctcc tcccagccca tggtaaccag catttgactc tttacttgta taagggcagc 2100
ttttataggt tccacatgta agtgagatca tgcagtgttt gtctttctgt gcctggetta 2160
tttcaactcag cataatgtgc accgggttca cccatgtttt cataaatgac aagatttcct 2220
cctttaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 2263

```

```

<210> SEQ ID NO 7
<211> LENGTH: 4491
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 7

```

```

cgaagatggc ggcgtcgcgt cgctctcagc atcatcacca ccacatcaa caacagctcc 60
agcccgcccc aggggcttca gcgcgcgcgc cgccacctcc tccccactc agccctggcc 120
tggccccggg gaccacccca gcctctccca cggccagcgg cctggcccc ttgcctccc 180
cgcggcacgg cctagcgtcg ccggaggggg atggcagtcg ggatccgccc gacaggcccc 240
gatccccgga cccggttgac ggtaccagct gttgcagtac caccagcaca atctgtaccg 300
tcgcgcgcgc tcccgtggtc ccagcgggtt ctacttcac tcgcgctggg gtgcgtccca 360
accagcgcgg cagtggcagt aacaattcac cgtcgtctc ttcttccccg actttctcct 420
catcttctc tccatcctcc cctggatcga gcttggcgga gagccccgag gcggccggag 480
ttagcagcac agcaccactg gggcctgggg cagcaggacc tgggacaggg gtcccagcag 540
tgagcggggc cctacgggaa ctgctggagg cctgtcgcaa tggggacgtg tcccgggtaa 600
agaggctggt ggacgcggca aacgtaaatg caaaggacat ggccggccgg aagtcttctc 660
ccctgcactt cgctgcagg tttggaagga aggatgttgt agaacactta ctacagatgg 720
gtgctaattg ccacgctcgt gatgatggag gtctcatccc gcttcataat gcctgttctt 780
ttggccatgc tgaggttgtg agtctgttat tgtgccagg agctgatcca aatgccaggg 840
ataactggaa ctatacacct ctgcatgaag ctgctattaa agggaagatc gatgtgtgca 900
ttgtgtctgt gcagcagcga gctgacccaa acattcgga cactgatggg aaatcagccc 960
tggacctggc agatccttca gcaaaagctg tccttacagg tgaatacaag aaagacgaac 1020
tcctagaagc tgctaggagt ggtaattgaa aaaaactaat ggctttactg actcctctaa 1080
atgtgaattg ccatgcaagt gatggcgaa agtcgactcc tttacatcta gcagcgggct 1140
acaacagagt tcgaatagtt cagcttctc ttcagcatgg tgcgtatgtt catgcaaaag 1200
acaaaggtag acttgtgcct cttcataatg catgttcata tggacattat gaagtcacag 1260
aactgctact aaagcatgga gcttgtgtta atgccatgga tctctggcag tttactccac 1320
tgcacgaggc tgcttccaag aaccgtgtag aagtctgctc tttgttactt agccatggcg 1380
ctgatcctac gttagtcaac tgccatggca aaagtgtgtt ggatatggct ccaactccgg 1440
agcttaggga gagattgact tatgaattta aaggtcattc tttactacaa gcagccagag 1500
aagcagactt agctaaagt aaaaaaacac tcgctctgga aatcattaat ttcaaaaaac 1560
cgcagtctca tgaaacagca ctgcactgtg ctgtggcctc tctgcatccc aaacgtaaac 1620
aagtgcagca attgttactt agaaaaggag caaatgttaa tgaaaaaat aaagatttca 1680
tgactccctc gcatgttgca gccgaaagag ccataatga tgcacatgga gttctgcata 1740
agcatggcgc caagatgaat gcactggaca cccttggtca gactgctttg catagagccg 1800

```

US 8,859,562 B2

25

26

-continued

| | |
|--|------|
| ccctagcagg ccacctgcag acctgccgcc tectgctgag ttacggctct gacccctcca | 1860 |
| tcattctcctt acaaggcttc acagcagcac agatgggcaa tgaagcagtg cagcagattc | 1920 |
| tgagtgtgag ttacggctct gacccctcca tcattctcctt acaaggcttc acagcagcac | 1980 |
| agatgggcaa tgaagcagtg cagcagattc tgagtggtea ttcgtagata gtgatcattc | 2040 |
| tacttcagcc ttaatgggtga tcttgagacg ggaagattta gaaggaaatc tatccagcat | 2100 |
| gtcttcactg tcaacatgaa gagtacacct atactgactt ctgatgttga ttatcgactc | 2160 |
| ttagaggcat ctaaagctgg agacttgaa actgtgaagc aactttgcag ctctcaaat | 2220 |
| gtgaattgta gagacttaga gggccggcat tccacgcctt tacacttcgc agcaggctac | 2280 |
| aacagagtac acctatacgt acttctgatg ttgattatcg actcttagag gcatctaaag | 2340 |
| ctggagactt ggaaactgtg aagcaacttt gcagctctca aaatgtgaat tgtagagact | 2400 |
| tagagggccg gcattccacg cctttacact tcgcagcagg ctacaaccgc gtgtctgttg | 2460 |
| tagagtacct gctacaccac ggtgccgatg tccatgcaa agacaagggt ggcttggtgc | 2520 |
| cccttcataa tgectgttca tatggacact atgaggtggc tgagctttta gtaaggcatg | 2580 |
| gggcttctgt caatgtggcg gacttatgga aatttacctt tctccatgaa gcagcagcta | 2640 |
| aaggaaagta tgaaatctgc aagctccttt taaaacatgg agcagatcca actaaaaaga | 2700 |
| acagagatgg aaatacacct ttggatttgg taaaggaagg agacacagat attcaggact | 2760 |
| tactgaaagg ggatgctgtt ttgttggtg ctgccaaaga gggctgcctg gcaagagtgc | 2820 |
| agaagctctg taccctcagag aatatcaact gcagagacac ccagggcaga aattcaacct | 2880 |
| ctctgcacct ggcagcagcg tataataacc tggaagtagc tgaatatctt cttagagcatg | 2940 |
| gagctgatgt taatgcccg gacaagggtg gtttaattcc tcttcataat gcggcatctt | 3000 |
| atgggcatgt tgacatagcg gctttattga taaaatacaa cacgtgtgta aatgcaacag | 3060 |
| ataagtgggc gtttactccc ctccatgaag cagcccagaa aggaaggacg cagctgtgcg | 3120 |
| ccctcctcct agcgcatggt gcagacccca ccatgaagaa ccagggaaggc cagacgcctc | 3180 |
| tggtactggc aacagctgac gatatcagag ctttgcctgat agatgccatg ccccagagg | 3240 |
| ccttacctac ctgtttttaa cctcaggcta ctgtagtgag tgcctctctg atctcaccag | 3300 |
| catccacccc ctctgcctc tcggctgcca gcagcataga caacctcact ggccctttag | 3360 |
| cagagtgggc cgtaggagga gcctccaatg caggggatgg cgcgcgggga acagaaagga | 3420 |
| aggaaggaga agttgctggt cttgacatga atatcagcca atttctaaaa agccttgggc | 3480 |
| ttgaacacct tcgggatatc tttgaaacag aacagattac actagatgtg ttggctgata | 3540 |
| tgggtcatga agagttgaaa gaaataggca tcaatgcata tgggcaccgc cacaaattaa | 3600 |
| tcaaaggagt agaaagactc ttaggtggac aacaaggcac caatccttat ttgacttttc | 3660 |
| actgtgttaa tcagggaacg attttgcctg atcttgcctc agaagataaa gaatatcagt | 3720 |
| cagtgaaga agagatgcaa agtactatc gagaacacag agatgggtgg aatgctggcg | 3780 |
| gcatcttcaa cagatacaat gtcattcgaa ttcaaaaagt tgtcaacaag aagttgaggg | 3840 |
| agcggttctg ccaccgacag aagggaagtgt ctgaggagaa tcacaacct cacaatgagc | 3900 |
| gcatgttgtt tcatggttct cctttcatta atgccattat tcataaaggg tttgatgagc | 3960 |
| gacatgcata cataggagga atgtttgggg ccgggattta ttttgcctgaa aactcctcaa | 4020 |
| aaagcaacca atatgtttat ggaattggag gaggaacagg ctgccctaca cacaaggaca | 4080 |
| ggcatgctta tatatgtcac agacaaatgc tcttctgtag agtgaccctt gggaaatcct | 4140 |
| ttctgcagtt tagcaccatg aaaatggccc acgcgcctcc agggcaccac tcagtcattg | 4200 |

US 8,859,562 B2

27

28

-continued

```

gtagaccgag cgtcaatggg ctggcatatg ctgaatatgt catctacaga ggagaacagg 4260
cataccaga gtatcttate acttaccaga tcatgaagcc agaagccct tcccagaccg 4320
caacagccgc agagcagaag acctagttaa tgctgtctgg tgaaggccag atcagatttc 4380
aacctgggac tggattacag aggattgttt ctaataacaa catcaatatt ctagaagtc 4440
ctgacagcct agaaataagc tgtttgtctt ctataaagca ttgctatagt g 4491

```

```

<210> SEQ ID NO 8
<211> LENGTH: 6189
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 8

```

```

cgcgccgct cgctagccga aacctgccca gccggtgccc ggccactgcg cagcgcgagg 60
acgacgtcac gtgcgctccc ggggctggac ggagctggca ggaggggct tgcagcttc 120
cgcgccgcg tgcgttcagg acccgagcgg cggtatcgcg ctgcctccgc cgcgcgagg 180
cagccggggg gcaggagacc cagcgagggg cgcgcggtgg cgcgccatg ggactgcgcc 240
ggatccggtg acagcaggga gccaaagcgg ccggggccctg agcgcgctct ctcgggggg 300
cctcgccctc ctgctcgcg ggccggggct cctgctccgg ttgctggcg tgttctggc 360
tgtggcgcg gccagatca tgctgggtcg ccgctgcgcc ggcgggggag cgccctgcgc 420
gagcgccgc gccagggcgg tggagccggc cgcccgagag ctgttcgagg cgtgccgcaa 480
cggggacgtg gaacgagtca agaggctggt gacgcctgag aaggtgaaca gccgcgacac 540
ggcgggcagg aaatccaccc cgctgcactt cgccgcaggt tttgggcgga aagacgtagt 600
tgaatatttg cttcagaatg gtgcaaatgt ccaagcacgt gatgatgggg gccttattcc 660
tcttcataat gcatgctctt ttggtcatgc tgaagtagtc aatctccttt tgcgacatgg 720
tgacagcccc aatgctcgag ataattggaa ttatactcct ctccatgaag ctgcaattaa 780
aggaaagatt gatgtttgca ttgtgctgtt acagcatgga gctgagccaa ccatccgaaa 840
tacagatgga aggacagcat tggatttagc agatccatct gccaaagcag tgcttactgg 900
tgaatataag aaagatgaac tcttagaaag tgccaggagt ggcaatgaag aaaaaatgat 960
ggctctactc acaccattaa atgtcaactg ccacgcaagt gatggcagaa agtcaactcc 1020
attacatttg gcagcaggat ataacagagt aaagattgta cagctgttac tgcaacatgg 1080
agctgatgtc catgctaaag ataaaggatg tctggtacca ttacacaatg cctgttctta 1140
tggtcattat gaagtaactg aacttttggt caagcatggt gcctgtgtaa atgcaatgga 1200
cttgtggcaa ttcactcctc ttcagtaggc agcttctaag aacagggttg aagtatgttc 1260
tcttctctta agttatgggt cagacccaac actgctcaat tgtcacaata aaagtgtctat 1320
agacttggct cccacaccac agttaaaga aagattagca tatgaattta aaggccactc 1380
gttctgcaa gctgcacgag aagctgatgt tactcgaatc aaaaaacatc tctctctgga 1440
aatggatgaat ttcaagcctc ctcaaacaca tgaacagca ttgcattgtg ctgctgcac 1500
tccatatccc aaaagaaagc aaatatgtga actgttgcta agaaaaggag caaacatcaa 1560
tgaaaagact aaagaattct tgactcctct gcacgtggca tctgagaaag ctcataatga 1620
tgttgttgaa gtagtggtga aacatgaagc aaaggttaat gctctggata atcttggtca 1680
gacttctcta cacagagctg catattgtgg tcatctacaa acctgccgcc tactcctgag 1740
ctatgggtgt gacctaaca ttatatccct tcagggtttt actgctttac agatgggaaa 1800

```

US 8,859,562 B2

29

30

-continued

| | |
|--|------|
| tgaaaatgta cagcaactcc tccaagaggg tatctcatta ggtaattcag aggcagacag | 1860 |
| acaattgctg gaagctgcaa aggctggaga tgtcgaaaact gtaaaaaaac tgtgtactgt | 1920 |
| tcagagtgtc aactgcagag acattgaagg gcgtcagtct acaccacttc attttgcagc | 1980 |
| tgggtataac agagtgtccg tgggtggaata tctgctacag catggagctg atgtgcatgc | 2040 |
| taaagataaa ggaggccttg tacctttgca caatgcatgt tcttatggac attatgaagt | 2100 |
| tgcagaactt cttgttaaac atggagcagt agttaatgta gctgatttat ggaaatttac | 2160 |
| acctttacat gaagcagcag caaaaggaaa atatgaaatt tgcaaaacttc tgctccagca | 2220 |
| tgggtgcagac cctacaaaaa aaaacaggga tggaaatact cctttggatc ttgttaaaga | 2280 |
| tggagataca gatattcaag atctgcttag gggagatgca gctttgctag atgctgccaa | 2340 |
| gaagggttgt ttagccagag tgaagaagt gtcttctcct gataatgtaa attgccgcga | 2400 |
| taccaaggc agacattcaa cacctttaca tttagcagct gggtataata atttagaagt | 2460 |
| tgcagagtat ttgttacaac acggagctga tgtgaatgcc caagacaaag gaggacttat | 2520 |
| tcctttacat aatgcagcat cttacgggca tgtagatgta gcagctctac taataaagta | 2580 |
| taatgcatgt gtcaatgcc cggacaaatg ggctttcaca cctttgcacg aagcagccca | 2640 |
| aaagggagca acacagcttt gtgctttgtt gctagcccat ggagctgacc cgactcttaa | 2700 |
| aaatcaggaa ggacaaacac ctttagattt agtttcagca gatgatgtca gcgctcttct | 2760 |
| gacagcagcc atgcccccat ctgctctgcc ctcttggtac aagcctcaag tgctcaatgg | 2820 |
| tgtgagaagc ccaggagcca ctgcagatgc tctctcttca ggtccatcta gcccatcaag | 2880 |
| cctttctgca gccagcagtc ttgacaactt atctgggagt ttttcagaac tgtcttcagt | 2940 |
| agttagtcca agtggaacag aggggtgcttc cagtttgag aaaaaggagg ttccaggagt | 3000 |
| agatttttagc ataactcaat tcgtaaggaa tcttggaact gagcacctaa tggatatatt | 3060 |
| tgagagagaa cagatcactt tggatgtatt agttgagatg gggcacaagg agctgaagga | 3120 |
| gattggaatc aatgcttatg gacataggca caaactaatt aaaggagtcg agagacttat | 3180 |
| ctccggacaa caaggtctta acccatattt aactttgaac acctctggta gtggaacaat | 3240 |
| tcttatagat ctgtctcctg atgataaaga gtttcagtct gtggaggaag agatgcaaag | 3300 |
| tacagttcga gagcacagag atggaggcca tgcagggtga atcttcaaca gatacaatat | 3360 |
| tctcaagatt cagaagggtt gtaacaagaa actatgggaa agatacactc accggagaaa | 3420 |
| agaagtttct gaagaaaacc acaaccatgc caatgaacga atgctatttc atgggtctcc | 3480 |
| ttttgtgaat gcaattatcc acaaaggctt tgatgaaagg catgcgtaca taggtgggtat | 3540 |
| gtttggagct ggcatttatt ttgctgaaaa ctcttccaaa agcaatcaat atgtatatgg | 3600 |
| aattggagga ggtactgggt gtccagtcca caaagacaga tcttggtaca ttgcccacag | 3660 |
| gcagctgctc ttttgccggg taaccttggg aaagtcttcc ctgcagtcca gtgcaatgaa | 3720 |
| aatggcacat tctcctccag gtcactcctc agtcactggg agggccagtg taaatggcct | 3780 |
| agcattagct gaatatgtta ttacagagg agaacaggct tatcctgagt atttaattac | 3840 |
| ttaccagatt atgaggcctg aaggtatggt cgatggataa atagtatttt taagaaacta | 3900 |
| attccactga acctaaaac atcaaagcag cagtggcctc tacgttttac tcctttgctg | 3960 |
| aaaaaaaaatc atcttgccca caggcctgtg gcaaaaggat aaaaatgtga acgaagttaa | 4020 |
| acattctgac ttgataaagc tttaataatg tacagtgttt tctaaatatt tctgttttt | 4080 |
| tcagcacttt aacagatgcc attccagggt aaactgggtt gtctgtacta aattataaac | 4140 |
| agagttaact tgaacctttt atatgttatg cattgattct aacaaactgt aatgccctca | 4200 |

US 8,859,562 B2

31

32

-continued

```

acagaactaa ttttactaat acaatactgt gttcttttaa acacagcatt tacactgaat 4260
acaatttcat ttgtaaaact gtaaataaga gcttttgtag tagcccagta tttatttaca 4320
ttgctttgta atataaatct gttttagaac tgcagcgggt tacaaaattt tttcatatgt 4380
attgttcate tatacttcat cttacatcgt catgattgag tgatctttac atttgattcc 4440
agaggctatg ttcagttggt agttgggaaa gattgagtta tcagatttaa tttgccgatg 4500
ggagccttta tctgtcatta gaaatcttct tcattttaaga acttatgaat atgctgaaga 4560
tttaatttgt gatacctttg tatgtatgag acacattcca aagagctcta actatgatag 4620
gtcctgatta ctaaagaagc ttccttactg gcttcaattt ctagctttca tgttgaaaa 4680
ttttctgcag tccttctgtg aaaattagag caaagtgtct ctgtttttta gagaaactaa 4740
atcttgctgt tgaacaatta ttgtgttctt ttcattggaac ataagtagga tgtaaacatt 4800
tccagggtgg gaagggtaat cctaaatcat tcccaatct attctaatta ccttaaatct 4860
aaaggggaaa aaaaaatca caaacaggac tgggtagttt tttatcctaa gtatattttt 4920
tctgttctt tttacttggt tttattgtg tatttatagc caatctatac atcatgggta 4980
aacttaacc agaactataa aatgtagttg tttcagtcct cttcaggcct cctgaatggg 5040
caagtgcagt gaaacagggt cttcctgtct ctgggttttc tctccatgat gttatgcca 5100
attggaata tgctgtcagt ttgtgcacca tatggtgacc acgctgtgc tcagtttggc 5160
agctatagaa ggaaatgctg tcccataaaa tgccatccct atttctaata taacactctt 5220
ttccaggaag catgcttaag catcttgta cagagacata catccattat ggcttgga 5280
tctcttttat ttgttgactg tagctccctt caaagtcgag gaaagatctt tactcactta 5340
atgaggacat tccccatcac tgtctgtacc agttcacctt tattttacgt tttattcagt 5400
ctgtaaatca actggccctt tgcagtaact tgtacataaa gtgctagaaa atcatgttcc 5460
ttgtcctgag taagagttaa tcagagtaag tgcatttctg gagttgttct tgtgatgtaa 5520
attatgatca ttatttaaga agtcaaatcc tgatcttgaa gtgcttttta tacagctctc 5580
taataattac aaatatccga aagtcatttc ttggaacaca agtggagtat gccaaatttt 5640
atatgaattt ttcagattat ctaagcttcc aggttttata attagaagat aatgagagaa 5700
ttaatggggt ttatatttac attatctctc aactatgtag cccatattac tcaccctatg 5760
agtgaatctg gaattgcttt tcattgtgaa tcattgtggt ctatgagttt acaatactgc 5820
aaactgtgtt attttatcta aaccattgct taatgagtgt gtttttccat gaatgaatat 5880
accgtggttc atatgttagc atggcagcat tttcagatag ctttttgttt gttgggaagt 5940
tgggggtttt gggggagggt gagtattagt acgttgcatg gaatagccta ctttataatg 6000
atgggaatgc tttttctttt gttttgggat tttttttttt gaagtgaat ttaacttttt 6060
gtgccagtag tactattata cccatcttca gtgtcttact tgtactgtat caaattccat 6120
accctcattt aattcttaat aaaactgttc acttgtaaaa aaaaaaaaaa aaaaaaaaaa 6180
aaaaaaaaa 6189

```

<210> SEQ ID NO 9

<211> LENGTH: 5490

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

cgcccgccca gccccggggg cagggaagc ctaaattacg gaattaccgc gagcaaggag 60

US 8,859,562 B2

33

34

-continued

| | | | | | | |
|------------|------------|-------------|-------------|-------------|------------|------|
| cgcggaatcg | gggagcgtcc | ggagctagct | ggatcctcta | ggcaggatgg | tgatgggaat | 120 |
| ctttgcaaat | tgtatcttct | gtttgaaagt | gaagtactta | cctcagcagc | agaagaaaaa | 180 |
| gctacaaact | gacattaagg | aaaatggcgg | aaagttttcc | ttttcgtaa | atcctcagtg | 240 |
| cacacatata | atcttagata | atgctgatgt | tctgagtcag | taccaactga | attctatcca | 300 |
| aaagaaccac | gttcatatgt | caaaccaga | ttttatatgg | aaatctatca | gagaaaagag | 360 |
| actcttggat | gtaaagaatt | atgatcctta | taagccctg | gacatcacac | cacctcctga | 420 |
| tcagaaggcg | agcagttctg | aagtgaatac | agaaggtcta | tgcccgaca | gtgccacaga | 480 |
| ggaggaagac | actgtggaac | tcactgagtt | tggtatgcag | aatgttgaaa | ttcctcatct | 540 |
| tcctcaagat | tttgaagttg | caaaatataa | caccttgag | aaagtgggaa | tgaggaggag | 600 |
| ccaggaagct | gtggtggtgg | agcttcagtg | ttcgccggac | tccagggact | gtcctttcct | 660 |
| gatatactca | cacttctctc | tggtatgatg | catggagact | agaagacagt | ttgctataaa | 720 |
| gaaaacctct | gaagatgcaa | gtgaatactt | tgaataattac | attgaagaac | tgaagaaaca | 780 |
| aggatttcta | ctaagagaac | atttcacacc | tgaagcaacc | caattagcat | ctgaacaatt | 840 |
| gcaagcattg | cttttgagg | aagtcataaa | ttcaagcact | ctgagccaag | aggtgagcga | 900 |
| tttagtagag | atgatttggg | cagagggcct | gggccacctg | gaacacatgc | ttctcaagcc | 960 |
| agtgaacagg | attagcctca | acgatgtgag | caaggcagag | gggatttctc | ttctagttaa | 1020 |
| ggcagcactg | aaaaatggag | aaacagcaga | gcaattgcaa | aagatgatga | cagagtttta | 1080 |
| cagactgata | cctcacaaa | gcacaatgcc | caaagaagtg | aacctgggac | tattggctaa | 1140 |
| gaaagcagac | ctctgccagc | taataagaga | catggttaat | gtctgtgaaa | ctaatttgtc | 1200 |
| caaaaccaac | ccaccatccc | tgcccaata | cagagctttg | aggtgcaaaa | ttgagcatgt | 1260 |
| tgaacagaat | actgaagaat | ttctcagggt | tagaaaagag | gttttgacga | atcatcacag | 1320 |
| taagagccca | gtggtgtctc | tcagatatt | tagagtggc | agagtgaatg | aaaccacaga | 1380 |
| gtttttgagc | aaacttggt | atgtgaggcc | ctgtgtgcat | ggttctctctg | tacaaaacat | 1440 |
| cgtgggaatc | ttgtgtcgag | ggttgctttt | acccaaagta | gtggaagatc | gtggtgtgca | 1500 |
| aagaacagac | gtcggaaacc | ttggaagtgg | gatttatctc | agtgatctgc | tcagtacaag | 1560 |
| tatcaagtac | tcacaccctg | gagagacaga | tggcaccaga | ctcctgctca | ttgtgacgt | 1620 |
| agccctcgga | aagtgtatgg | acttacatga | gaaggacttt | cccttaactg | aagcaccacc | 1680 |
| aggctacgac | agtgtgcatg | gagtttcaca | aacagcctct | gtcaccacag | actttgagga | 1740 |
| tgatgaattt | gttgtctata | aaaccaatca | ggttaaaatg | aaatatatta | ttaaattttc | 1800 |
| catgcttgga | gatcagataa | aggactttca | tcctagtgat | catactgaat | tagaggaata | 1860 |
| cagacctgag | ttttcaaatt | tttcaaaggt | tgaagattac | cagttaccag | atgccaaaac | 1920 |
| ttccagcagc | accaaggccg | gcctccagga | tgctctctgg | aacttggttc | ctctggagga | 1980 |
| tgccacatc | aaaggagaaa | tcatagacac | tgtagccag | gtcattgttt | ttcagacata | 2040 |
| cacaaataaa | agtcacgtgc | ccattgaggc | aaaatatatc | tttccttttg | atgacaaggc | 2100 |
| cgctgtgtgt | ggcttcgaag | ccttcacata | tggaagcac | atagttggag | agattaaaga | 2160 |
| gaaggaagaa | gccagcaag | agtaacctaga | agccgtgacc | cagggccatg | gcgcttacct | 2220 |
| gatgagtcag | gatgctccgg | acgtttttac | tgtaagtgtt | ggaaacttac | cccctaaggc | 2280 |
| taaggttctt | ataaaaaata | cctacatcac | agaactcagc | atcctgggca | ctgttggtgt | 2340 |
| ctttttcatg | cccgcaccg | tagcaccctg | gcaacaggac | aaggctttga | atgaaaacct | 2400 |
| tcaggatata | gtagagaaga | tttgtataaa | agaaatagga | acaagcaaaa | gcttctcttt | 2460 |

US 8,859,562 B2

35

36

-continued

| | |
|---|------|
| gactatgtct attgagatgc cgtatgtgat tgaattcatt ttcagtata cecatgaact | 2520 |
| gaaacaaaag cgcacagact gcaaagctgt cattagcacc atggaaggca gctccttaga | 2580 |
| cagcagtgga ttttctctcc acatcgggtt gtctgctgcc tatctccaa gaatgtgggt | 2640 |
| tgaaaaacat ccagaaaaag aaagcgaggc ttgcatgctt gtctttcaac ccgatctcga | 2700 |
| tgtegacctc cctgacctag ccagtgcagc cgaagtgcatt atttgtcttg actgctccag | 2760 |
| ttccatggag ggtgtgacat tcttgcaagc caagcaaatc accttgcatg cgtgtctcct | 2820 |
| gggtgggtgag aagcagaaaag taaatattat ccagttcggc acagggtaca aggagctatt | 2880 |
| ttcgtatcct aagcatatca caagcaaatc cacggcagca gagttcatca tgtctgccac | 2940 |
| acctaccatg gggaacacag acttctggaa aacctccga tatcttagct tattgtaccc | 3000 |
| tgctcgaggg tcacggaaca tctctcgtgt gtctgatggg cacctccagg atgagagcct | 3060 |
| gacattacag ctctggaaga ggagccggcc gcacaccagg ttattcgcct gcggtatcgg | 3120 |
| ttctacagca aatcgtcacg tcttaaggat tttgtcccag tgtgggtgcc gagtatattga | 3180 |
| atattttaat gcaaaatcca agcatagttg gagaaaacag atagaagacc aaatgaccag | 3240 |
| gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc | 3300 |
| gcccagggcc ctgcaggccc cagcccaggt gccatccttg tttcgcaatg atcgactcct | 3360 |
| tgtctatgga ttcattcttc actgcacaca agcaactctg tgtgcactaa ttcaagagaa | 3420 |
| agaattttgt acaatgggtg cgactactga gcttcagaag acaactggaa ctatgatcca | 3480 |
| caagctggca gcccagagct taatcagaga ttatgaagat ggcatctctc acgaaaatga | 3540 |
| aaccagtcct gagatgaaaa aacaaacctt gaaatctctg attattaaac tcagtaaaaga | 3600 |
| aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaagg atgagaatga | 3660 |
| gtcgcctttt cctgatatto caaaagtctc tgaacttatt gccaaagaag atgtagactt | 3720 |
| cctgccctac atgagctggc agggggagcc ccaagaagcc gtcaggaacc agtctctttt | 3780 |
| agcatcctct gagtggccag aattacgttt atccaaacga aaacatagga aaattccatt | 3840 |
| ttccaaaaga aaaatggaat tatctcagcc agaagtttct gaagattttg aagaggatgg | 3900 |
| cttaggtgta ctaccagctt tcacatcaaa tttggaacgt ggaggtgtgg aaaagctatt | 3960 |
| ggatttaagt tggacagagt catgtaaac aacagcaact gaaccactat ttaagaaagt | 4020 |
| cagtcocatg gaaacatcta cttctagctt ttttctatt ttggctccgg ccgttggttc | 4080 |
| ctatcttacc ccgactacct gcgctcacag tctgtcttcc ttgtcttttg cctcatatcg | 4140 |
| tcaggtagct agtttcgggt cagctgctcc tcccagacag ttgatgcct ctcaattcag | 4200 |
| ccaaggccct gtgcctggca cttgtgctga ctggatccca cagtcggcgt cttgtccac | 4260 |
| aggacctccc cagaacctac cttctgcacc ctattgtggc attgtttttt cagggagctc | 4320 |
| attaagctct gcacagtctg ctccactgca acatcctgga ggctttacta ccaggccttc | 4380 |
| tgctggcacc ttccctgagc tggattctcc ccagcttcat ttctctcttc ctacagaccc | 4440 |
| tgatcccatc agaggttttg ggtcttatca tccctctgct tactctcctt ttcattttca | 4500 |
| accttcgca gcctctttga ctgccaacct taggctgcca atggcctctg ctttacctga | 4560 |
| ggctctttgc agtcagtcac ggactacccc agtagatctc tgtcttctag aagaatcagt | 4620 |
| aggcagcttc gaaggaaagt gatgtcctgt ctttgctttt caaagttctg acacagaaa | 4680 |
| tgatgagcta tcagaagtac ttcaagacag ctgcttttta caaataaagt gtgatacaaa | 4740 |
| agatgacagt atcccgtgct ttctggaatt aaaagaagag gatgaaatag tgtgcacaca | 4800 |

US 8,859,562 B2

37

38

-continued

```

acactggcag gatgctgtgc cttggacaga actcctcagt ctacagacag aggatggctt 4860
ctggaaactt acaccagaac tgggacttat attaaatctt aatacaaatg gtttgacacag 4920
ctttcttaaa caaaaaggca ttcaatctct aggtgtaaaa ggaagagaat gtctcctgga 4980
cctaattgcc acaatgctgg tactacagtt tattegcacc aggttggaag aagaggggaat 5040
agtgttcaaa tcaactgatga aaatggatga ccttcttatt tccaggaata ttccctgggc 5100
ttttgaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc 5160
tatctgcccc cggttgaac tggggaacga ctgggactct gccaccaagc agttgctggg 5220
actccagccc ataagcactg tgtccctctt tcatagagtc ctccattaca gtcaaggcta 5280
agtcaaatga aactgaattt taaacttttt gcatgcttct atgtagaaaa taatcaaatg 5340
ataatagata attataatga aacttcatta aggtttcatt cagtgtagca attactgtct 5400
ttaaaaatta agtgaagaa gaattacttt aatcaactaa caagcaataa taaaatgaaa 5460
cttaaaataa aaaaaaaaaa aaaaaaaaaa 5490

```

The invention claimed is:

1. A method of treatment of cancer cells defective in homologous recombination (HR), the method comprising: identifying a human patient with a familial predisposition to gene-linked hereditary cancer,

25

wherein said cancer comprises cancer cells defective in homologous recombination; identifying a compound which inhibits PARP-1, and administering to said human patient a therapeutically effective amount of said compound.

* * * * *